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ABSTRACT 
USE OF NOVEL ASSAYS TO MEASURE IN VIVO BASE EXCISION DNA REPAIR 
by Preethi Sundaresakumar 
Oxidative DNA damage due to reactive oxygen species (ROS) can cause 
single-base alterations such as 8-oxo-7,8-dihydroguanine (8oxodG) lesions, which are 
repaired by the base excision DNA repair (BER) pathway. Assays developed to date, to 
measure BER, are limited by in vitro analysis and use of radiolabeled reagents. This 
thesis outlines the design of a novel assay to measure the kinetics of BER in vivo, using a 
biotin-tagged oligonucleotide DNA substrate that contains an 8oxodG lesion. The 
substrate DNA is transfected into target cells and incubated to allow repair of the lesions. 
The DNA is then captured following cell lysis and the disappearance of 8oxodG lesions 
is monitored using competitive 8oxodG ELISA. This assay was developed to corroborate 
the results obtained from our investigations on the role of the breast cancer susceptibility 
protein-1 (BRCA1) in BER, using another novel in vivo assay called the host-cell 
reactivation (HCR) assay. Preliminary results from this study showed that BRCA1 is 
involved in BER. Together, these in vivo assays may be used to identify potential cancer 
genes that regulate the BER pathway. 
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INTRODUCTION 
Cellular DNA constantly faces assault from various endogenous and exogenous 
agents. Nucleotides are oxidized on exposure to reactive oxygen species (ROS) which 
are generated endogenously during various cellular metabolic processes (Friedberg et al., 
2006a, chap. 2). Oxidized guanine products such as 8-oxo-7,8-dihydroguanine (8oxodG) 
are common ROS-induced single base alterations. Unless repaired, oxidative DNA 
damage results in genetic instability and tumorigenesis. The base excision DNA repair 
(BER) pathway is the major cellular pathway that corrects oxidation-induced single base 
alterations (David, O'Shea, & Kundu, 2007; Dizdaroglu, 2005; Mitra, Boldogh, Izumi, & 
Hazra, 2001; Seeberg, Eide, & BJ0ras, 1995). 
A number of assays have been developed to monitor BER activity. These assays 
have been used to identify the various steps and the proteins involved in the pathway. In 
addition, they allow comparison of repair activity in different cell types following 
exposure to oxidative stress. However, such assays are limited due to the need for in 
vitro analyses using cell extracts and the use of radiolabeled reagents. 
In this study, we have designed a novel assay to measure BER of 8oxodG lesions 
in vivo, and optimized the working conditions for some of the steps in the assay. This 
assay measures the repair of a short double-stranded oligonucleotide DNA substrate 
carrying a single 8oxodG lesion on one strand and a 3' biotin tag on the complementary 
strand. Following transfection of the substrate DNA into target cells and incubation to 
allow time for repair, the cells are lysed, and the biotin-tagged substrate DNA is captured 
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using streptavidin-coated magnetic beads. The 8oxodG lesions on the substrate DNA are 
then quantified using a competitive 8oxodG enzyme-linked immunosorbent assay 
(ELISA). The amount of 8oxodG lesions quantified is inversely proportional to the 
efficiency of BER in the cells. 
The in vivo BER assay was designed to corroborate the preliminary results 
obtained from another study conducted as part of this thesis. This study involved the 
investigation of the role of the breast cancer susceptibility protein-1 (BRCA1) in the BER 
pathway, using a novel host-cell reactivation assay (HCR) for BER that was recently 
developed in our laboratory. This assay for BER monitors the ability of cells in culture to 
remove transcription-blocking 8oxodG lesions introduced ex-vivo into a green fluorescent 
protein (GFP) reporter gene in a recombinant adenovirus. Repair of the 8oxodG lesions 
by the cellular BER pathway allows for expression of GFP, which can be measured using 
standard fluorescence detection methods. In our study, a wild-type BRCA1 expression 
vector was transfected into BRCA1 deficient cells, and the cells were subjected to the 
HCR assay. Preliminary results show that the BRCA1 protein enhances the BER 
pathway. 
This thesis has been divided into two chapters. In the first chapter, the 
preliminary investigations on the role of the BRCA1 protein in BER using the HCR assay 
have been described. In the second chapter, the development of a novel assay to measure 
the in vivo BER of 8oxodG lesions has been described. In the following section, an 
overview of oxidative DNA damage, 8oxodG lesions, and the BER pathway has been 
provided, to serve as an introduction to the two chapters that follow. 
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Oxidative DNA Damage 
Cellular DNA is susceptible to oxidation by ROS and transition metals (Neely & 
Essigmann, 2006). In the cell, ROS are by-products of aerobic metabolism. They are 
also generated during metabolism of xenobiotic compounds (Park et al., 2005) and 
phagocytosis (Bogdan, Rollinghoff, & Diefenbach, 2000). ROS may also be introduced 
exogenously by radiation, redox cycling compounds, drugs, or cigarette smoke 
(Friedberg et al., 2006a, chap. 2). Different types of ROS include superoxide (O2 ), 
hydroxyl (OH), peroxyl (R02), alkoxyl (RO), hydroperoxyl (HO2 ), singlet oxygen 
(]02), peroxynitrite (ONOO), and hydrogen peroxide (H2O2). A cell usually decreases 
ROS levels using free radical scavengers and antioxidant enzymes (Pacifici & Davies, 
1991). When these defenses fail, elevated ROS levels cause damage to nucleic acids, 
proteins, carbohydrates, and lipids in a cell (Friedberg et al., 2006a, chap. 2). 
ROS induce the formation of a plethora of DNA oxidation products (Bjelland & 
Seeberg, 2003), some of which are 8oxodG, thymine glycol, formaminopyrimidine, and 
5-hydroxycytosine. It is usually the electrophilic carbon centers of the bases that are 
oxidized (Nilsen & Kroken, 2001). If left unrepaired, oxidized bases lead to 
apurinic/apyrimidic (AP) sites and strand breaks (Friedberg et al., 2006a, chap. 2), and 
result in DNA mutations, genetic instability, and cancer. Oxidized bases and AP sites are 
mainly repaired using the BER pathway (Seeberg et al , 1995). Some oxidative lesions 
also appear to be repaired by the nucleotide excision repair (NER) and mismatch repair 
(MMR) pathways (Bjelland & Seeberg, 2003). Strand breaks may be repaired by 
homologous recombination (HR) or non-homologous end-joining (NHEJ) mechanisms. 
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8-oxo- 7,8-dihydroguanine (8oxodG) 
Among the ROS-induced DNA oxidation products, guanine oxidation products 
occur most frequently. This is because guanine, owing to its low reduction potential 
(Ej = 1.29 V) (Neely & Essigmann, 2006; Steenken & Jovanovic, 1997), is more 
susceptible to oxidation (Bjelland & Seeberg, 2003). A guanine oxidation product that 
has been thoroughly examined and is often used as a biomarker of cellular oxidative 
stress is 8oxodG (David et al., 2007) (Figure 1). 
H,N 
DNA 
Figure 1. Chemical formula of 8-oxo-7,8-dihydroguanine. 
8oxodG lesions are highly stable and mutagenic. Their stability is evidenced by 
the fact that these lesions were detected among eight oxidative base modifications in 
ancient DNA (Hoss, Jaruga, Zastawny, Dizdaroglu, & Paabo, 1996). In the anti 
conformation, they form 8oxodG {anti) - C {anti) base pair. However, in the syn 
conformation, they mimic thymidine and thus form a stable 8oxodG {syn) - A {anti) base 
pair (David et al., 2007). Such base pairing specificities allow bypass of 8oxodG lesions 
by replicative DNA polymerases (Shibutani, Takeshita, & Grollman, 1991) and this 
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ultimately results in GC to TA transversion mutations (Cheng, Cahill, Kasai, Nishimura, 
& Loeb, 1992). In humans, a set of three enzymes (called the GO system) are involved in 
the repair of 8oxodG lesions. The enzyme MutT homolog 1 (MTH1) hydrolyzes 
8oxodGTP bases from the nucleotide pool, thereby preventing their incorporation into 
DNA. The human 8-hydroxyguanine DNA glycosylase (hOGGl), functions in the first 
step of the BER pathway to specifically detect and excise the 8oxodG lesion from the 
8oxodG-C base pair. If 8oxodG is not removed by hOGGl, then following replication, 
the 8oxodG base pairs with adenine. The enzyme MutY homolog (MUTYH) then 
removes the adenine from the 8oxodG-A base pair, and allows the incorporation of a 
cytosine opposite the 8oxodG base. This provides another opportunity for the hOGGl 
enzyme to excise the 8oxodG lesion (Friedberg et al., 2006b, chap. 6). 
Base Excision DNA Repair (BER) 
To deal with the constant assaults faced by cellular DNA, repair pathways have 
evolved, each specializing in the correction of certain types of damage. The BER 
pathway, first discovered by Tomas Lindahl in 1974, specializes in the repair of small 
base alterations that do not distort the DNA helix (Fromme & Verdine, 2004). Besides 
oxidized bases, the BER pathway also recognizes and repairs alkylated bases (formed due 
to base exposure to S-adenosylmethionine and tobacco-specific nitosamines), AP sites 
(formed by the spontaneous loss of purines from DNA) and deaminated bases (resulting 
from hydrolytic deamination of amine-containing DNA bases) (Fromme & Verdine, 
2004). 
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The BER system consists of a group of lesion-specific enzymes termed DNA 
glycosylases, which recognize and excise specific base modifications, resulting in AP 
sites. Other enzymes act in a series of steps to fill in the missing base, and ultimately 
restore the correct sequence (Krokan, Nilsen, Skorpen, Otterlei, & Slupphaug, 2000). 
Since the focus of this thesis is on the repair of oxidized bases (particularly 8oxodG), a 
brief description of the steps involved in the BER of 8oxodG lesions is given below. 
The hOGGl glycosylase is the mammalian DNA glycosylase that recognizes and 
excises the 8oxodG lesion from 8oxodG-C base pairs. The enzyme removes 8oxodG 
lesions via displacement using a nucleophile active-site residue, which is an amine 
(Fromme & Verdine, 2004). Following displacement of 8oxodG, hOGGl catalyses the 
cleavage of the N-glycosyl bond between the lesion and deoxyribose in the backbone, 
resulting in an AP site. Being a bifunctional DNA glycosylase, hOGGl has both DNA 
glycosylase and DNA lyase activities. Thus, following removal of the 8oxodG lesion, the 
lyase activity allows the enzyme to cleave the DNA backbone on the 3' side of the lesion 
resulting in the generation of a 3'-a, P-unsaturated aldehyde end and a 5' phosphate end. 
The human apurinic/apyrimidic endonuclease 1 (APE1) then removes the 
3'-a, |3-unsaturated aldehyde by virtue of its 3'- phosphodiesterase activity. This results in 
a single nucleotide gap that is flanked by 3' hydroxyl and 5' phosphate ends. DNA 
polymerase P then fills the gap and the strand is resealed by DNA ligase III and X-ray 
Repair Complementing Defective Repair in Chinese Hamster Cells 1 (XRCC1) 
heterodimers (Figure 2A) (Friedberg et al., 2006b, chap. 6; Fromme & Verdine, 2004; 
Hirano, 2008). 
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Studies have shown that in the presence of APE 1, the hOGGl lyase activity is 
bypassed (Vidal, Hickson, Boiteux, & Radicella, 2001). APE1 then directly cleaves the 
backbone at the 5' side of the AP site resulting in the formation of a 3' hydroxyl end and a 
5' deoxyribose phosphate (dRP) end. Beyond this step, repair can proceed in one of two 
alternative pathways which involve either the replacement of one (short-patch BER) or 
more nucleotides (long-patch BER) at the lesion site (Fortini et al., 2003). It has been 
shown that hOGGl-mediated repair of 8oxodG occurs almost exclusively along the 
short-patch pathway (Fortini, Parlanti, Sidorkina, Laval, & Dogliotti, 1999). In 
short-patch BER (SP-BER), following cleavage by APE1, DNA polymerase P removes 
the 5'-dRP due to its intrinsic dRPase activity and then fills in the gap due to its DNA 
polymerase activity. The strand is then resealed by DNA ligase III and XRCC1 
heterodimers, or DNA ligase I (Figure 2B) (Friedberg et al., 2006b, chap. 6; Fromme & 
Verdine, 2004). 
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Figure 2.. Base excision repair of 8oxodG lesions in mammalian cells. The hOGGI 
enzyme excises the 8oxodG base (O) in an 8oxodG-C base pair, resulting in an AP site. 
Using its lyase activity (A), the enzyme then cleaves the DNA backbone on the 3' side of 
the lesion resulting in the generation of a 3'-a, [3-unsaturated aldehyde end (*) and a 5' 
phosphate (P) end. The APE1 enzyme then removes the 3'-a, P-unsaturated aldehyde, 
thereby creating a single nucleotide gap that is flanked by 3' hydroxyl (OH) and 5' 
phosphate (P) ends. DNA polymerase P (Pol P) then fills the gap and the strand is 
resealed by a DNA ligase III/XRCC1 heterodimer. Alternatively (B), the hOGGI lyase 
activity is bypassed and following 8oxodG base excision, APE1 directly cleaves the 
backbone at the 5' side of the AP site resulting in the formation of a 3' hydroxyl end (OH) 
and a 5' deoxyribose phosphate (dRP) end. Following cleavage by APE1, Pol p removes 
the 5'-dRP, and then fills in the single nucleotide gap. The strand is then resealed by the 
DNA ligase III and XRCC1 heterodimer or DNA ligase I. 
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CHAPTER ONE 
INVESTIGATION ON THE ROLE OF BRCA1 IN BER USING 
THE HOST-CELL REACTIVATION ASSAY 
Introduction 
The Breast Cancer Susceptibility Gene-1 (BRCA1) 
The BRCA1 gene was mapped to chromosome 17q21 by Miki et al. in 1994. It 
contains 24 exons that encode a 220 kDa protein of 1863 amino acids. The protein 
consists of multiple functional domains; a highly conserved N-terminal Really Interesting 
New Gene-1 (RING) finger domain (residues 1-112), two centrally located 
nuclear-localization signals (NLS), an 'SQ' cluster domain (SCD) containing serine and 
glutamine residues (residues 1280-1524), and two BRCA1 carboxy terminal (BRCT) 
domains (residues 1646-1863) (Deng, 2006; Venkitaraman, 2001). 
The BRCA1 protein functions as a tumor suppressor and has been implicated in a 
number of cellular activities such as cell cycle checkpoint control, centrosome 
duplication, chromatic remodeling and transcription, replication, recombination, DNA 
repair, ubiquitination and apoptosis (reviewed in Daniel, 2002; Deng, 2006; Scully, Xie, 
& Nagaraju, 2004; Starita & Parvin, 2003; Venkitaraman, 2001; Yarden & Papa, 2006). 
Deng (2006) proposed that a loss of these functions may be responsible for the gross 
genetic instability observed in BRCA1 -mutated mouse and human mammary tumors 
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(Weaver et al., 2002; Xu et al, 1999). A study (Tirkkonen et al., 1997) also showed that 
BRCA1 -associated breast cancers have high levels of chromosomal aneuploidy when 
compared to breast carcinomas lacking a BRCA1 mutation. While on one hand, this 
genetic instability triggers DNA damage response pathways leading to growth arrest and 
activation of pro-apoptotic signals, on the other hand, the cell continues to accumulate 
mutations in critical tumor regulatory genes, including p53, PTEN, Rbl, ErbB2, c-Myc, 
p27, and cyclin Dl, that initiate carcinogenesis (Brodie et al., 2001; Deng, 2006; Xu et 
al., 1999). 
BRCA1-Associated Breast Cancers 
Breast cancer is the second leading cause of cancer mortality in Western women 
(Deng, 2006). About 10% of breast cancer cases are heritable; the remaining being 
sporadic cases (Easton & Peto, 1990). Approximately 50% of heritable breast cancer 
cases and 80% of combined breast and ovarian cancer cases occur due to mutations in 
BRCA1 (Yarden & Papa, 2006). More than 90% of the identified germ-line BRCA1 
mutations introduce premature termination codons into the BRCA1 coding sequence; 
most of the truncated BRCA1 mRNA transcripts are degraded by the nonsense-mediated 
mRNA decay pathway (Perrin-Vidoz, Sinilnikova, Stoppa-Lyonnet, Lenoir, & Mazoyer, 
2002). Thus, the level of BRCA1 truncated proteins expressed (if any) is very low. 
Among sporadic cases of BRCA 1 -associated breast cancer, epigenetic silencing of 
BRCA1 in the form of promoter hypermethylation rather than BRCA1 mutations is 
commonly seen (Catteau & Morris, 2002). This results in the loss of BRCA 1 gene 
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expression. A few studies have also attributed the low expression ofBRCAl in sporadic 
breast cancers to the degradation of BRCA1 proteins (Blagosklonny et al., 1999) and/or 
transcriptional repression of the BRCA1 gene (Budhram-Mahadeo, Ndisang, Ward, 
Weber & Latchman, 1999). 
BRCA1 and Base Excision DNA Repair 
As mentioned previously (in the "Introduction" section of this thesis), several 
endogenous and exogenous factors are responsible for cellular oxidative stress. In 
addition to those factors, a breast-specific mechanism is also responsible for oxidative 
stress in breast tissues: the accumulation of hydrogen peroxide following the metabolism 
of 17(3-estradiol by lactoperoxidase (Sipe, Jordan, Hanna, & Mason, 1994). Under these 
conditions, if the cellular antioxidant defense systems and/or DNA repair systems are 
compromised, the DNA begins to rapidly accumulate oxidative damage, resulting in 
genetic instability and initiation of breast carcinoma (Malins & Haimanot, 1991). 
Previous studies in our laboratory (Alii, 2008) showed that mouse mammary 
epithelial cells deficient in BRCA1 had higher levels of oxidative DNA damage (oxidized 
bases were measured using the comet assay) when compared to cells containing the 
wild-type BRCA1. In addition, BRCA1 -mutated breast cancer cell lines (SUM149PT, 
SUM1315M02, HCC1937, and MDAMB436) were found to be more sensitive to 
treatment with hydrogen peroxide when compared to normal (but immortalized) breast 
cell lines (MCF10A and MCF12A) (Alii, 2008). Since BER is the major pathway that 
repairs oxidative DNA damage, and a direct correlation between resistance to oxidative 
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DNA damage and cellular BRCA1 levels was seen in previous studies, we decided to 
investigate if BRCA1 was involved in the BER pathway. 
In this study, we hypothesized that the BRCA1 protein plays a role in BER, and 
so breast tissue with low BRCA1 expression or with a mutant BRCA1 has defective BER, 
and thus increased oxidative DNA damage. This may then result in genetic instability 
leading to the initiation and progression of breast carcinogenesis. For our study, we used 
the SUM149PT breast cancer cell line. This is an adherent, ductal epithelial cell line that 
originated from the inflammatory breast carcinoma of a 35 year old patient (Elstrodt et 
al., 2006). The genome copy number aberrations and gene expression profile of this cell 
line has been previously studied (Neve et al., 2006). SUM149PT cells have a deletion 
(2288delT) in exon 11 of the BRCA1 coding region, which results in a premature 
termination codon (Elstrodt et al., 2006) in the mRNA transcript. Semiquantitative 
RT-PCR analysis has previously confirmed the presence of very low levels (Elstrodt et 
al., 2006) or complete absence (Alii, 2008) of BRCA1 mRNA transcripts in these cells, 
which could be due to the nonsense-mediated decay of the truncating transcripts. This is 
also consistent with previous results obtained following Western blot analysis (Alii, 
2008; Elstrodt et al., 2006) and immuno-histochemistry (Elstrodt et al., 2006) on paraffin 
embedded cells, which showed the complete absence of BRCA1 proteins in the nucleus 
of SUM149PT cells. To test our hypothesis, a constitutive wild-type BRCA1 expression 
plasmid was transfected into the SUM149PT cells. Cells transfected with the empty 
vector alone were used as a negative control. The transfected cells were then subjected to 
a novel host-cell reactivation assay (HCR) to measure in vivo BER activity. 
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Materials and Methods 
Cell Lines and Media 
SUM149PT cells (Asterand) were cultured in Ham's F12 media (Gibco) 
supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Gibco), IX 
penicillin/streptomycin/fungizone (P/S/F) (Mediatech Inc.), 5 |J.g/ml insulin (Sigma 
Aldrich), 1 ug/ml hydrocortisone (Sigma Aldrich) and 10 mM HEPES (Gibco). Their 
morphology, growth rate, and lack of BRCA1 gene expression was regularly monitored in 
our laboratory (using RT-PCR and Western blotting). The earliest passages of the cell 
line were used for our experiments. MCF7 cells were cultured in media containing 
DMEM (Mediatech Inc), 10% FBS and IX P/S/F. All the cells were maintained in 
5% CO2 at 37 °C. The cells were frozen in media containing 10% (vol/vol) DMSO. 
Confirmation of the Wild-Type BRCA1 Construct and the Empty Vector Control 
The wild-type BRCA1 expression plasmid (pcDNA3fi-BRCAl) and the empty 
vector control (pcDNA3) were kindly provided by Dr. Simon Powell (Washington 
University, St. Louis). The constructs were transformed into the OneShot® TOP 10 
chemically competent E.coli cells (Invitrogen) according to the manufacturer's 
instructions. Each transformation mix was then plated on LB agar plates containing 
100 |j,g/ml ampicillin (Sigma Aldrich), and the plates were inverted, and incubated at 
37 °C overnight. Single, well-isolated colonies were picked and grown overnight in 
sterile snap-capped polystyrene tubes containing 3 ml of LB/ampicilin (100 ug/ml) media 
at 37 °C, 250 rpm. Plasmids were isolated from 2 ml of each cell suspension using the 
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GenElute™ Plasmid Miniprep Kit (Sigma Aldrich), and their DNA concentration was 
estimated using UV-Vis spectrophotometry (BioPhotometer, Eppendorf). The remaining 
cell suspension was stored at 4 °C to prepare frozen glycerol stocks, once the positive 
clones were identified following restriction analysis. 
If restriction analysis was not performed on the same day that the plasmids were 
isolated, then prior to plasmid isolation, cell suspensions from each sample were spotted 
on a grid-plate containing LB agar with 100 fig/ml ampicillin, and labeled. The plates 
were sealed and stored at 4 °C. Following identification of positive clones, cell 
suspensions were prepared from the corresponding grids as described before. 
For the restriction analysis of the pcDNA3P-i?i?C47 construct, unique restriction 
sites on the pcDNA3 vector backbone (Invitrogen) and the BRCA1 coding sequence 
(Genbank accession number NM_007294) were identified using Webcutter 2.0 
(developed by Heiman, 1997). Two restriction sites {Nhel, Xhol) on the 
pcDNA3 fi-BRCAl construct which on cutting would yield restriction fragments of 
unequal sizes, that would be easily detectable following gel analysis, were chosen. The 
pcDNA3 constructs were digested using the restriction enzyme Pstl, as suggested by the 
manufacturer. 
Plasmids (2.5 \ig) isolated from the pcDNA3fi-BRCAl transformed clones were 
digested at 37 °C for 2 hr with Nhel (30 U) (Gibco BRL) in React 4 buffer (Gibco BRL), 
followed by digestion at 37 °C for 1 hr withZfcoI (20 U) (NEB) in NEB 2 buffer (NEB). 
Plasmids obtained from pcDNA3 transformed clones were digested with Pstl (30 U) 
(NEB) at 37 °C for 3 hr. A final concentration of 100 (ig/ml of bovine serum albumin 
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(BSA) (NEB) was included in the Pstl restriction digest. The restricted plasmids were 
electrophoresed on a 1% agarose gel (containing 3 ug of ethidium bromide per ml of 
molten agarose) in Tris acetate EDTA (TAE) buffer, along with a 1 kb DNA ladder 
(Invitrogen). The DNA fragments on the gel were visualized using 300 nm UV 
illumination (Chemilmager 4400, Alpha Innotech). 
Large Scale Amplification of the Wild-Type BRCA1 Construct and Empty Vector Control 
for Use in Transfection 
Prior to transfection, a small amount of frozen culture from the pcDNA3$-BRCAl 
and pcDNA3 glycerol stocks was removed and streaked on LB agar plates with 
100 iag/ml ampicillin and incubated overnight at 37 °C. A single colony was removed 
and suspended in sterile snap-cap polystyrene tubes containing 2 ml of LB/ampicillin 
media (100 |ig/ml) to prepare starter cultures. The tubes were then incubated at 37 °C, 
250 rpm, for 8 hr. The starter cultures were then diluted 1/1000 into 100 ml of 
LB/ampicillin media (100 (J-g/ml) in a 500 ml flask and incubated overnight at 37 °C, 
250 rpm. The plasmids were then isolated using HiSpeed Plasmid Maxi Kit (Qiagen) 
according to manufacturer's instructions, and quantified using UV-Vis 
spectrophotometry. The plasmid DNA was then stored at -20 °C until transfection. 
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Transient Transfection of the Wild-Type BRCA1 Construct and Empty Vector Control 
into SUM149PT Cells 
The day before transfection, SUM149PT cells were plated at approximately 
100 cells/cm2 growth area of a T-25 tissue culture flask using regular growth media. 
Prior to transfection, cells were washed once with IX phosphate-buffered saline (PBS) 
and replenished with 2 ml of Opti-MEM® I Reduced Serum Medium (Invitrogen). The 
pcDNA3p-5i?C4i (10 ng) and pcDNA3 (10 u.g) plasmids were transfected into the 
SUM149PT cells using Lipofectamine™ 2000 (10 ul) (Invitrogen), according to the 
manufacturer's instructions. A cell control that was treated only with Lipofectamine™ 
2000 (10 (0.1) was included to monitor cytotoxicity from the transfection reagent. The 
cells were incubated at 37 °C in a CO2 incubator for 24 hr (the media in the flasks was 
replaced with regular growth media 6 hr after transfection). 
Nuclear Protein Extraction and Quantification 
The SUM149PT cells were collected into microfuge tubes 24 hr following 
transfection, by scraping using a rubber policeman. The cells were pelleted by 
centrifugation at 1500 rpm for 5 min, and washed once with ice-cold IX PBS. Nuclear 
proteins from these cells were extracted using the NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents Kit (Pierce), according to the manufacturer's instructions. A 
protease inhibitor cocktail (Sigma Aldrich P8340) was added to the reagents specified by 
the manufacturer. The concentration of nuclear proteins extracted was then determined 
using the Bio-Rad Protein Assay (Biorad), according to the manufacturer's instructions 
16 
for the microtiter plate format. BSA was used as the standard, and the absorbance at 
595 nm was measured using a microplate reader (Molecular Devices, Inc.). 
Western Blot Analysis 
The nuclear proteins (20 ug) were denatured by boiling for 5 min in Laemmli 
Sample Buffer (Biorad), and resolved at 100 V on a Ready Gel Tris-HCl gradient gel 
(4-15%) (Biorad) using IX Tris-glycine-SDS Buffer (Biroad). The Kaleidescope 
Prestained Standards (Biorad) were included as molecular weight markers. Following 
electrophoresis, the gel was equilibrated in IX Tris-glycine Buffer (Biorad) containing 
20% (vol/vol) methanol. The proteins were then blotted overnight at 4 °C, onto a 
polyvinylidene fluoride (PVDF) membrane (Amersham Biosciences) using the 
Mini-Protean 3 transfer system (Biorad) (20 V), according to the manufacturer's 
instructions. Following transfer, the membrane was removed from the transfer system, 
oriented and blocked using 5% (wt/vol) milk for 1 hr at room temperature. Following a 
brief wash in phosphate-buffered saline containing 0.05% (vol/vol) Tween-20 (PBST), 
the entire membrane was cut horizontally, between the 130 kDa and 87 kDa molecular 
weight markers (identified by the colors of the markers). The portion of the membrane 
containing the 130 kDa and 205 kDa markers were probed overnight at 4 °C with 
anti-BRCAl monoclonal antibody (2 ug/ml) (Calbiochem) in 1% (wt/vol) milk and 
PBST. The other portion of the membrane containing markers between the molecular 
weights 7 kDa to 87 kDa, were probed for the TATA-binding protein (TBP) (a nuclear 
loading control) using anti-TBP monoclonal antibody (1/2000) (Abeam) in 1% (wt/vol) 
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milk and PBST. Following a brief wash, the two portions of the membrane were 
incubated in ECL peroxidase labeled anti-mouse antibody (1/5000) (Amersham 
Biosciences), 3% (wt/vol) milk and PBST for 1 hr at room temperature. The membrane 
was then rinsed three times in PBST, treated with ECL Western Blotting Detection 
Reagents (Amersham Biosciences) according to the manufacturer's instructions, and 
exposed on a HyperFilm ECL (Amersham Biosciences). The film was processed 
(Konica SRX-101A Film Processor) following a 20 min exposure for BRCA1 and 1 min 
exposure for TBP. 
Use of the Host-Cell Reactivation (HCR) Assay to Measure BER in SUM149PT Cells 
Transiently Transfected with Wild-Type BRCA1 or Empty Vector Constructs 
Overview of the HCR assay for BER. The HCR assay to measure BER of 8oxodG 
lesions was developed by Dr. Elizabeth Alii (Ford laboratory, Stanford University). This 
assay uses recombinant adenovirus carrying a reporter gene coding for GFP (Ad-GFP). 
Photodynamic treatment (PDT) of DNA, which involves treatment of DNA with a 
photosensitizing dye and exposure to visible light, has previously been shown to 
introduce 8oxodG lesions (Schneider, Price, Maidt, Gutteridge, & Floyd, 1990). PDT of 
adenoviral virions using methylene blue (as a photosensitizer) and visible light has been 
shown to specifically induce damage to the DNA with little effect on the viral capsid 
(Schagen et al., 1999). In the HCR assay, the Ad-GFP virions are subjected to PDT to 
induce the formation of transcription-blocking 8oxodG lesions on the GFP reporter gene. 
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The damaged GFP reporter gene is then introduced into cells of interest via 
adenovirus-mediated gene transfer, and allowed sufficient time for repair. If the 8oxodG 
lesions on the GFP reporter gene are successfully repaired by the cellular BER pathway, 
the gene undergoes host-cell reactivation, and GFP is expressed. Thus, expression of 
GFP (detected using a fluorescence plate reader) indicates successful repair, whereas lack 
of GFP indicates compromised repair (Figure 3). 
Ad-GFP Oxidative DNA damage 
Taget cell infection 
Figure 3. Overview of the host-cell reactivation assay to measure BER of 8oxodG 
lesions. Recombinant adenoviruses containing a GFP reporter gene (Ad-GFP) are 
subjected to photodynamic treatment (methylene blue and visible light) which induces 
8oxodG lesions (O) on the GFP reporter gene, thus preventing its expression. Following 
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infection of the target cells, if cellular BER is efficient, the lesions are repaired and GFP 
is expressed. However, if cellular BER is compromised, the lesions are not repaired and 
no GFP is expressed. Reproduced with permission from the author (Alii, 2006). 
Transient transfection of the wild-type BRCA1 and empty vector constructs into 
SUM149PT cells for the HCR assay. SUM149PT cells were plated 24 hr before 
transfection on nine wells (2 x 105 cells/well) of a 24-well plate. Three wells were 
transfected with the pcDNA3 empty vector control (1 ug/well) and labeled "Vector 
Control". The next three wells were transfected with the pcDNA3$-BRCAl expression 
vector (1 (j.g/well) and were labeled "BRCA1 WT". The last three wells were left 
untransfected and were labeled "Cell Control" (Table 1). The transfections were 
performed using Lipofectamine ™ 2000 (1 ul/well) (Invitrogen), according to the 
manufacturer's instructions. After 6 hr of incubation at 37 °C with 5% CO2, the cells 
were replenished with 300 ul of regular growth media and further incubated for 10-15 hr, 
to allow expression of the wild-type BRCA1. 
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Table 1 
Designation of wells for the plating, transfection and infection of SUM149PT cells in the 
HCR assay 
Position of well (24-well plate) Designation of well 
Al 
Bl 
CI 
Vector control - "Count" 
Vector control - "Undamaged" 
Vector control - "Damaged" 
A2 
B2 
C2 
BRCA1 WT - "Count" 
BRCA1 WT - "Undamaged" 
BRCA1 WT - "Damaged" 
A3 
B3 
C3 
Cell control - "Count" 
Cell control - "Undamaged" 
Cell control - "Damaged" 
Note. Vector control = SUM149PT cells transfected with pcDNA3 empty vector; 
BRCA1 WT = SUM149PT cells transfected with pcDNA3p-5i?C47 expression vector; 
Cell control = untransfected SUM149PT cells; Count = well of cells that was trypsinized 
and counted; Undamaged = well of cells infected with the undamaged Ad-GFP viruses 
(exposed to only the photosensitizer); Damaged = well of cells infected with the damaged 
Ad-GFP viruses (exposed to both the photosensitizer and visible light). 
PDT and adenoviral infection. One well of cells (labeled "Count") from each of the 
three sets of wells labeled "Vector control", "BRCA1 WT" and "Cell control" (Table 1) 
was trypsinized, and the cells were counted using a hemacytometer. SUM149PT cells 
are typically infected with 50 pfu of adenovirus per cell. The number of cells counted per 
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well was then used to estimate the total volume of Ad-GFP virions required for infection. 
While one batch of the Ad-GFP virions (labeled "Damaged") was subjected to PDT (i.e., 
treatment with 0.5 uM methylene blue and exposure to 2 mW/cm visible light) for 
1 min, another batch (labeled "Undamaged") was treated only with 0.5 uM methylene 
blue but not exposed to visible light. The PDT was carried out in the dark. In order to 
reduce heat damage to the virus, the PDT was performed on ice and a dish of sterile water 
was used between the light source and the plate containing the virus, to absorb heat. The 
cells in the wells labeled "Damaged" and "Undamaged" (Table 1) were then infected 
with the damaged virus (50 pfu/cell) and undamaged virus (50 pfu/cell) respectively. The 
infection was carried out in the dark. The infected cells were then incubated at 37 °C 
with 5% CO2 for 24 hr (the cells were washed with IX PBS and replenished with regular 
growth media 4 hr after infection). 
HCR analysis. The cells were washed 24 hr following infection, trypsinized, and 
resuspended in regular growth media. The cells were centrifuged at 1500 rpm for 5 min, 
washed once with IX PBS, and resuspended in 500 ul of IX PBS. The cells were then 
counted and the cell suspensions were normalized to the sample containing the lowest 
cell number, in a final volume of 500 ul of IX PBS. Each sample (100 ul) was aliquoted 
in quadruplicates on to a black 96-well plate. Wells containing only IX PBS were used 
to record background fluorescence. GFP expression was measured using a fluorescence 
plate reader (Flexstation 11-384, Molecular Devices Inc.), and calculated as a ratio of the 
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fluorescence readings from cells infected with the damaged virus to those infected with 
the undamaged virus. 
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Results 
Confirmation of the Wild-Type BRCA1 Construct and the Empty Vector Control 
Prior to use in the transfection of SUM149PT cells, the pcDNA3$-BRCAl and the 
pcDNA3 constructs that were kindly provided by Dr. Simon Powell were confirmed by 
DNA restriction analysis. While the restriction enzyme to use (PstY) for the analysis of 
the pcDNA3 vector was specified by the manufacturer (Invitrogen), the enzymes to use 
for the confirmation of the pcDNA3p-#/?C4./ construct were unknown. Thus, the 
Webcutter 2.0 program was used to generate a list of restriction enzymes that uniquely 
cut the BRCA1 coding sequence and the pcDNA3 vector backbone in the 
pcDNA3(3-5i?C4i construct. From this list, Nhel (uniquely cuts the BRCA1 coding 
sequence) and Xhol (uniquely cuts the vector backbone) enzymes were chosen, because 
these enzymes when used to cut the pcDNA3 $-BRCAl construct will generate two 
fragments of unequal sizes (1940 bp and 9766 bp) that can be easily visualized on an 
agarose gel. 
Following restriction analysis of the plasmids isolated from the pcDN A3 $-BRCAl 
and the pcDNA3 transformed bacterial clones, the products of restriction were run on a 
1% TAE-agarose gel (Figure 4). All the clones tested were found to be positive for the 
respective vectors. The plasmids isolated from the clones transformed with the pcDNA3 
vector, following digestion with Pstl (lanes 3 to 6), gave two bands of expected sizes 
(1385 bp and 4061 bp) as specified by the manufacturer. Following digestion with Nhel 
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and Xhol, the plasmids isolated from the clones transformed with the wild-type BRCA1 
construct (lanes 7 and 8) gave two bands of the expected sizes (1940 bp and 9766 bp). 
Lanes: 1 
6p 
10,000 
9000 
800QJ 
7000 
Sooo 
4000 
3 
2000-
*=— -9766 
-1940 
-13-85 
Figure 4. Restriction analysis of the plasmids isolated from bacterial clones transformed 
with the wild-type BRCA1 or the pcDNA3 constructs. Plasmids isolated from bacterial 
clones following transformation with the wild-type BRCA1 and pcDNA3 constructs were 
digested with NheUXhol and Pstl respectively, and electrophoresed on a 
1% TAE-agarose gel (stained with ethidium bromide). Lanes 1,9 = empty; lane 2 = 1 kb 
DNA ladder; lanes 3,4,5,6 = Pstl restricted plasmids from pcDNA3 transformed clones; 
lanes 7, 8= NheUXhol restricted plasmids from pcDNA3(3-#RCAi transformed clones. 
Bp = base pair. 
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Confirmation of Wild-Type BRCA1 Expression in SUM149PT Cells Transfected with the 
pcDNA3/3-BRCAl Expression Vector 
Prior to analysis of the nuclear extracts from SUM149PT cells transfected with 
wild-type BRCA1, nuclear extracts from a positive control cell line (MCF7) was analyzed 
by Western blotting using the anti-BRCAl monoclonal antibody. The antibody was 
found to specifically recognize the 220 kDa BRCA1 protein (Figure 5A). In our study, 
transfection of the SUM149PT cells with the empty pcDNA3 vector showed no BRCA1 
protein expression, whereas transfection of the pcDNA3P-Z?i?CA7 construct into these 
cells showed the presence of BRCA1 proteins in the nucleus (Figure 5B). 
A MICF7 B SUM149PT 
Lanes: 1 2 
BRCA1 
Figure 5. Western blot analysis of nuclear extracts from MCF7 cells and SUM149PT 
cells transfected with wild-type BRCA1 or the empty vector constructs. Nuclear extracts 
from MCF7 cells (A) were collected, subjected to SDS-PAGE gel electrophoresis using a 
4-15% gradient Tris-HCl gel. The proteins were blotted onto a PVDF membrane and the 
TM 
membrane was probed using anti-BRCAl monoclonal antibody and ECL peroxidase 
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labeled anti-mouse antibody. TATA-binding protein (TBP) was used as a nuclear 
loading control. Nuclear extracts from SUM149PT cells (B) transfected with either the 
empty pcDNA3 vector (lane 1) or the wild-type BRCA1 construct (lane 2) were analyzed 
as described for the MCF7 cells. kDa = kilo Dalton. 
BER Activity in SUM149PT Cells Transiently Transfected with Wild-Type BRCA1 and 
Empty Vector Control 
The HCR assay was performed to detect the efficiency of BER in SUM149PT 
cells transiently transfected with the wild-type BRCA1 and the empty vector constructs. 
The green fluorescence from GFP expression was recorded in wells containing an equal 
number of transfected (with pcDNA3 or BRCA1 constructs) SUM149PT cells that were 
infected either with the undamaged or damaged Ad-GFP virus. The relative GFP 
expression in the BRCA1 wild-type or empty vector transfected SUM149PT cells was 
then calculated as a ratio of the fluorescence readings obtained from cells infected with 
the damaged virus to those infected with the undamaged virus (Figure 6). An 
approximately two-fold increase in relative GFP expression in cells transfected with the 
wild type BRCA1 expression vector, when compared to those transfected with the empty 
pcDNA3 vector was observed. Untransfected SUM149PT cells subjected to the HCR 
assay showed similar relative GFP expression (0.6) when compared to that of cells 
transfected with the pcDNA3 vector (0.5). This shows that the vector backbone in the 
wild-type BRCA1 construct did not enhance BER activity. 
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Figure 6. Relative GFP expression from the HCR assay to measure BER in SUM149PT 
cells transfected with wild-type BRCA1 or empty vector constructs. SUM149PT cells 
transiently transfected with either the empty vector control (SUM149PT pcDNA3) or the 
wild-type BRCA1 expression vector (SUM149PT BRCA1) were subjected to the HCR 
assay to measure BER as described in the Methods section. The green fluorescence was 
recorded in quadruplicate wells (for each cell type) containing an equal number of cells, 
using a fluorescence plate reader. The relative GFP expression for each cell type was 
calculated as a ratio of the average fluorescence obtained for cells infected with the 
damaged virus to that of the undamaged virus. Each bar represents the average of the 
relative GFP expression for each cell type from two independent experiments. Vertical 
lines represent standard errors of the means. 
A few modifications to the assay methodology was later made (Alii, 2008), which 
included the use of the same cell numbers for measuring GFP expression in each 
experiment, in order to compare results obtained from different experiments. Using these 
modifications, when the assay was later repeated several times (Alii, 2008), an 
approximately four-fold increase in relative GFP expression from cells transfected with 
the wild-type BRCA1 construct when compared to those transfected with the empty 
vector control, was observed. 
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Discussion 
BRCA1 has been known as a "caretaker" of the genome (Kinzler & Vogelstein, 
1997) due to its role in multiple cellular processes that maintain genomic integrity. It has 
been implicated in the HR and NHEJ pathways to repair DNA double-stranded breaks 
(Zhang & Powell, 2005; Zhuang et al., 2006), and in the transcription-coupled repair 
(TCR) (Wang et al., 2000) and global genomic repair (GGR) (Hartman & Ford, 2002) 
sub-pathways of NER. However, the role of BRCA1 in the BER pathway was unknown. 
A direct correlation between cellular levels of BRCA1 and resistance to oxidative 
stress has previously been reported in prostrate cancer cells (DU-145) (Bae et al., 2004) 
and in mouse mammary epithelial cells (Alii, 2008). BRCA1 was found to up-regulate 
the expression of antioxidant genes in the study conducted by Bae et al. (2004). 
Although this may explain the BRCA1-mediated resistance to oxidative stress, we 
wanted to investigate if BRCA1 was involved in the BER pathway. 
A breast cancer cell line (SUM149PT) known to contain a BRCA1 truncation 
mutation (2288delT) that resulted in an absence of BRCA1 protein expression was 
chosen for our study. A wild-type BRCA1 expression vector and the empty vector 
(lacking the BRCA1 coding sequence) were confirmed by restriction analysis prior to 
their transfection into SUM149PT cells. These plasmids were previously sequenced and 
were found to contain no mutations (Scully et al., 1996). Due to the large size of the 
BRCA1 expression plasmid (which would require the use of multiple primers), we did not 
re-sequence the plasmid following restriction analysis. However, following transfection 
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of SUM149PT cells with the wild-type BRCA1 construct, we detected (by Western 
blotting) the presence of full-length BRCA1 proteins in the nucleus. This also suggests 
that the BRCA1 proteins were functional, since truncated BRCA1 proteins have been 
shown to be unable to translocate into the nucleus to form nuclear foci and function in 
DNA damage response (Scully et al., 1999). The SUM149PT cells transfected with the 
wild-type BRCA1 expression vector or the empty vector were subjected to the HCR assay 
to monitor in vivo BER activity. Results from our study suggested that SUM149PT cells 
expressing wild-type BRCA1 proteins have enhanced BER activity. 
BRCA1 may enhance BER activity through transcriptional regulation or direct/ 
indirect interactions with the proteins involved in the pathway. An immunoprecipitated 
BRCA1 protein complex containing USF2, a transcription factor, has been shown to 
specifically bind a novel consensus DNA sequence (TTC(G/T)GTTG) (Cable et al., 
2003). Screening of the regulatory regions of genes directly or indirectly involved in 
BER for this consensus DNA sequence, may enable identification of BER genes (if any) 
that are transcriptionally regulated by BRCA1. BRCA1 has been shown to interact with 
components of the basal transcriptional machinery such as RNA polymerase II 
holoenzyme and histone deacetylases (Lane, 2004; Monteiro, 2000). Thus, it may 
nonspecifically regulate transcription of BER related genes. BRCA1 may also facilitate 
the access of BER proteins to the oxidized bases through its association with the 
chromatin remodeling proteins SW1 and SNF (Bochar et al., 2000). 
The tumor suppressor p53 has been shown to enhance the hOGGl- and 
APE 1-mediated cleavage steps in the BER pathway (Achanta & Huang, 2004). BRCA1, 
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through its interaction with p53 (Zhang et al , 1998), may indirectly regulate BER 
activity. On the other hand, BRCA1 may interact directly with the proteins involved in 
BER through its BRCT domain. This domain, found in the carboxyl terminal end of the 
BRCA1 protein, is often found in other proteins involved in DNA repair and maintenance 
of genomic stability (Yarden & Papa, 2006). Such proteins have the ability to form 
homo- and heterodimers through the interaction of their BRCT domains (Caldecott, 
2003). The XRCC and Ligase III proteins involved in BER have been shown to 
heterodimerize through their BRCT domains (Dulic et al., 2001). It is likely that 
heterodimerization of the BRCA1 protein with either of these proteins could enhance 
their activity in the BER pathway. 
In conclusion, preliminary investigations in our study have shown that BRCA1 
enhances the BER pathway. These results will have to be confirmed using another assay 
for BER. Although it has been shown that immortalized cell lines retain many of the 
characteristics of the primary tissue (Neve et al., 2006), upon long-term culture, they may 
acquire new mutations in vitro. Thus, in the future, it may be useful to monitor BER in 
BRCA1 -mutated primary breast cancer cells, before and after transfection with a BRCA1 
expression vector. Besides the up-regulation of antioxidant genes, the putative 
involvement of BRCA 1 in the BER pathway suggests yet another mechanism by which 
the tumor suppressor may resist oxidative DNA damage in mammary tissue. The lack of 
these critical functions may explain the increased susceptibility to oxidative DNA 
damage previously observed in BRCA 1 -mutated breast cancer cells. Future research on 
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the precise role of BRCA1 in the BER pathway may facilitate the development of 
improved therapeutic strategies for BRCA1-associated breast and ovarian cancers. 
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CHAPTER TWO 
DEVELOPMENT OF A NOVEL ASSAY TO MEASURE IN VIVO BER 
Introduction 
The 8oxodG lesions are one of the most frequently observed oxidation products 
(Poulsen, Prieme, & Loft, 1998) and have been commonly used as indicators of cellular 
oxidative stress. These lesions are excised by the hOGGl DNA glycosylase (Rosenquist, 
Zharkov, & Grollman, 1997) and repaired primarily using the BER pathway (Lindahl, 
1993). The efficiency of cellular BER of 8oxodG lesions may be measured using one of 
two methods. The first method involves monitoring the disappearance of 8oxodG lesions 
with time, on genomic DNA, following induction of cellular oxidative stress. The second 
method involves monitoring the disappearance of 8oxodG lesions on a DNA repair 
substrate either in vitro or in vivo. 
Nonsubstrate Based Methods to Measure BER 
Some of the techniques available to measure BER do not use DNA repair 
substrates. Instead, they measure BER of 8oxodG lesions by monitoring the 
disappearance of the lesions on cellular genomic DNA, following exposure of the cells to 
oxidizing agents. High performance liquid chromatography with electrochemical 
detection (HPLC-ECD) has been used to measure 8oxodG bases on genomic DNA, 
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following digestion of DNA using nuclease PI and alkaline phosphatase (Anson, Hudson, 
& Bohr, 2000; Degan et al., 1995; Floyd, Watson, Wong, Altmiller, & Rickard, 1986). 
This method is expensive, requires a large sample volume and is capable of generating 
artifacts during sample preparation and chromatography (Ravanat et al., 2002). A 
common enzymatic method used to measure cellular 8oxodG levels following induction 
of oxidative stress involves the conversion of the 8oxodG lesions into DNA strand breaks 
using formamidopyrimidine DNA glycosylase. The breaks are subsequently detected 
using the comet assay (reviewed by McKelvey-Martin, Green, Schmezer, Pool-Zoberl, & 
Collins, 1993). This assay is inexpensive, requires very small amounts of DNA, and 
enables detection of heterogeneity in a cell population by measuring damage in single 
cells (Collins, Cadet, Moller, Poulsen, & Vina, 2004). However, this assay may 
sometimes underestimate 8oxodG levels due to inaccessibility of the lesions to the 
enzyme (occurs when the lesions are present in DNA loops) and due to the insensitivity 
of the assay above a certain level of DNA breakage (occurs when the tail end of the 
comet is saturated) (Collins & Dusinska, 2002; Collins et al., 2008). In addition, the 
assay is difficult to reproduce and requires careful optimization of experimental 
conditions to avoid detection of nonspecific strand breakage. 
Other assays use fluorescein isothiocyanate (FITC) conjugated 8oxodG binding 
proteins to detect cellular 8oxodG lesions by fluorescence microscopy or flow cytometry, 
following exposure of cells to oxidizing agents. Although simple and inexpensive, these 
methods suffer from high levels of background fluorescence due to either nonspecific 
binding of the FITC-conjugated proteins, or high basal levels of endogenous 8oxodG 
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lesions which occur as a result of cellular metabolism. As a result, the assay is not 
sensitive enough to detect differences in 8oxodG levels before and after treatment with 
oxidizing agents (unpublished observations, Ford laboratory). 
Immunoaffinity based methods for the detection and quantification of 8oxodG 
lesions have been previously described (Degan, Shigenaga, Park, Alperin, & Ames, 1991; 
Musarrat & Wani, 1994; Yin et al., 1995). An immunoaffmity-chromatography based 
8oxodG ELISA using monoclonal antibodies (Yin et al., 1995) showed results 
comparable to those obtained using HPLC. Depending on the specificity of the antibody 
used, ELISA is a convenient, sensitive and relatively inexpensive assay to quantify 
8oxodG lesions. A number of commercial 8oxodG ELISA kits (Trevigen Inc., Japan 
Institute for the Control of Aging, Genox Corp.) have recently been developed to 
measure 8oxodG levels in urine and serum samples. However, besides 8oxodG lesions, 
these kits can also detect and quantify RNA-based guanine oxidation products. If these 
kits were to be used with genomic DNA, they would then not only measure 8oxodG 
levels on the DNA, but also measure guanosine or its oxidation products (such as 
8-bromoguanosine, 8-mercaptoguanosine, and N2-methylguanosine, etc.) on any 
contaminating RNA. Thus, when used with genomic DNA, these kits may not reliably 
indicate the efficiency of cellular BER of 8oxodG lesions. 
Substrate Based Methods to Measure BER 
In vitro studies using cell extracts and plasmid DNA substrates have greatly 
advanced our understanding of the enzymology and steps involved in the repair of 
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8oxodG lesions (Dianov, Bischoff, Piotrowski, & Bohr, 1998; Fortini et al., 1999; Hazra, 
Izumi, Maidt, Floyd, & Mitra, 1998). However, one study (Cappelli, Degan, & Frosina, 
2000) reported the poor repair of 8oxodG lesions in vitro, using cell extracts from human 
fibroblast GM5757. In vitro BER may not be an accurate model of in vivo repair due to 
potential modifications of physiological conditions, disruption of repair protein 
complexes, interference from reagents in cell lysis buffers, and inconsistencies in the 
performance of cell extracts. In addition, the use of radiolabeled reagents in most of the 
in vitro assays further imposes cost and safety limitations. 
The HCR assay described in chapter one is an in vivo (cell-based) BER assay, 
that monitors the repair of 8oxodG lesions on the GFP-coding region of recombinant 
adenoviruses (Ad-GFP). Although it measures repair in vivo, it is an end-point assay; the 
repair of 8oxodG lesions is measured by the expression of functional GFP 24 hr after 
infection. Thus, the HCR assay cannot obtain steady-state measurements of in vivo BER. 
In this study, we have designed a novel assay to measure the in vivo BER of 
8oxodG lesions using a biotin-tagged oligonucleotide DNA substrate, containing a single 
8oxodG lesion on the untagged DNA strand (target strand). Briefly, the assay involves 
the transfection of the biotin-tagged substrate DNA into target cells and incubation for an 
increasing period of time to allow repair of the 8oxodG lesions. The cells are then lysed 
and the biotin-tagged substrate DNA is captured on streptavidin-coated beads and 
denatured, to isolate the untagged target DNA strand from the biotin-tagged 
complementary DNA strand. The 8oxodG lesions on the target DNA strands are then 
measured using the HT 8oxodG competitive ELISA Kit (Trevigen Inc.). The amount of 
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lesions detected on the target DNA is inversely proportional to the efficiency of cellular 
BER. When used with the tagged substrate DNA in this assay, the 8oxodG ELISA may 
provide a more reliable estimate of the efficiency of cellular 8oxodG BER when 
compared to its use with genomic DNA, because the tagged substrate DNA can be 
captured and purified from any contaminating DNA or RNA. 
This chapter describes the design of this novel assay for measuring BER of 
8oxodG lesions and optimization of the experimental conditions for some of the steps in 
the assay. The optimal working conditions for the assay were determined from the last 
step of the assay to the first, and each section of this chapter has been written in the same 
order. That is, the optimization experiments were performed first for the ELISA step of 
the assay, followed by the binding of the biotin-tagged substrate DNA to the 
streptavidin-coated beads, its denaturation and quantification, and finally, the transfection 
of the substrate DNA into target cells. This order was chosen since knowledge of the 
minimal amount of DNA required for the ELISA would enable an estimation of the 
amount of DNA to be used for titration of the streptavidin-coated beads, and ultimately 
for transfection. 
In the future, following validation of the assay in vivo, it may be used to identify 
potential cancer genes that regulate the BER pathway. 
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Materials and Methods 
Single-Stranded DNA Oligonucleotides 
The following oligonucleotide DNA strands were used to prepare the substrate 
and control DNA: 
1. Biotinylated DNA strand (nontarget DNA strand) (Operon) 
The nontarget DNA strand (28-mer) has a biotin-TEG tag at the 3' end and 
consists of the following sequence: 
5'-GCAGCCCGGGGGATCCACTAGTTCTAAG-Bt-3' (where Bt represents Biotin). 
2. + 8oxodG DNA strand (target DNA strand) (Midland Certified Reagents) 
The target DNA strand (24-mer) has a single 8oxodG lesion at position 10 (from 
the 5' end) and consists of the following sequence: 
5'-GAACTAGTGOATCCCCCGGGCTGC-3' (where O represents 8oxodG) 
3. -8oxodG DNA strand (control DNA strand) (Operon) 
The control DNA strand (24-mer) is identical in nucleotide sequence to the target 
DNA strand, but with a guanine instead of the 8oxodG lesion at position 10. It has the 
following sequence: 5"-GAACTAGTGGATCCCCCGGGCTGC-3'. 
Gel Analysis of the Single-Stranded DNA Oligonucleotides 
The single-stranded +8oxodG, -8oxodG and biotinylated DNA oligonucleotides 
were resuspended in IX Tris-EDTA (TE) buffer, aliquoted, and stored at -20 °C. The 
DNA oligonucleotides (50 ng) were then denatured by heating at 90 °C for 5 min in a 
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solution containing 95% (vol/vol) formamide, 30% (vol/vol) glycerol, 0.25% (wt/vol) 
bromophenol blue and 0.25% (wt/vol) xylene cyanol FF (Sambrook, Fritsch, & Maniatis, 
1989). The denatured DNA samples were placed on ice until they were ready to load 
onto a 15% Tris-borate-EDTA (TBE)-polyacrylamide 7 M urea gel. The gel was prerun 
for 30 min at 110 V. The samples were then loaded and electrophoresed at 110 V for 
approximately 1 hr. A 10 bp DNA ladder (Integrated Technologies) was denatured as 
described for the samples, and included in the gel. The DNA bands were visualized 
using 300 nm UV illumination (Chemilmager 4400, Alpha Innotech), following staining 
with SYBR® Green II (Invitrogen) according to the manufacturer's instructions. SYBR® 
Green II was used because it binds with higher affinity to single-stranded than 
double-stranded DNA (Invitrogen). 
Preparation of the Substrate and Control DNA 
Annealing. The substrate DNA (+ 8oxodG/biotinylated DNA) and the control DNA 
(- 8oxodG/biotinylated DNA) were prepared by annealing the single-stranded 
oligonucleotides as previously described (Achanta & Huang, 2004). Briefly, the 
+8oxodG or -8oxodG DNA strands (2 pmol/|j.l) and the biotinylated DNA strands 
(1 pmol/(il) were mixed in an annealing buffer consisting of a final concentration of 
10 mM Tris-hydrochloride (Tris-HCl) (pH 7.5), 5 mM magnesium chloride, and 30 mM 
sodium chloride (NaCl). The solution was heated to 85 °C and allowed to gradually cool 
to room temperature. The annealed DNA was aliquoted and stored at -20 °C. 
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Quantification. The annealed substrate and control DNA were quantified by 
fluorimetry using SYBR® Green I (Invitrogen). The NoLimits™ 25 bp DNA fragment 
(Fermentas) was used to generate a DNA standard curve ranging from 0-500 ng/ml. The 
SYBR® Green I dye was diluted (1/5000), and 500 ul of the diluted dye was added to 
500 ul of diluted annealed DNA (1/100 or 1/1000), and the solution was mixed well. 
Following incubation at room temperature (in the dark) for 5 min, 200 ul aliquots of the 
solution were loaded in quadruplicate wells of a black 96-well plate. Fluorescence was 
recorded using a fluorescence plate reader (Flexstation 11-384, Molecular Devices Inc.) at 
the excitation and emission wavelengths of 497 nm and 520 nm respectively. 
Gel analysis. The annealed substrate and control DNA (25 ng) were mixed with 
30% (vol/vol) glycerol, 0.25% (wt/vol) bromophenol blue and 0.25%o (wt/vol) xylene 
cyanol FF (Sambrook et al., 1989), and electrophoresed at 110 V on a 
15% nondenaturing TBE-polyacrylamide gel. The gel was stained using SYBR Green I 
(Invitrogen) according to the manufacturer's instructions, and visualized using 300 nm 
UV illumination. A 10 bp DNA ladder (Invitrogen) was also included. 
8oxodG Competitive ELISA 
The reagents from the HT 8oxodG ELISA Kit (Trevigen), including the 8oxodG 
coated ELISA plate, the standards consisting of 8oxodG bases and the anti-8oxodG 
antibody, were used to quantify 8oxodG lesions in our BER assay. The ELISA was 
performed according to the manufacturer's instructions. Briefly, the 8oxodG standards 
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and the single-stranded +8oxodG or -8oxodG DNA (5 ng each) were added to triplicate 
wells (50 ul/well) of the 96-well plate precoated with 8oxodG lesions. Then, diluted 
anti-8oxodG monoclonal antibody (50ul/well) was added, the plate was covered, and 
incubated at 37 °C for 1 hr. Following incubation, the wells were washed six times with 
the IX wash buffer provided (200ul/weli). Diluted horseradish peroxidase (HRP) 
conjugated anti-mouse secondary antibody (100 ul/well) was then added; the plate was 
covered and incubated for 1 hr at 37 °C. The wells were then washed as described 
before. The 3,3',5,5' - tetramethylbenzidine (TMB) substrate (100 ul/well) was added to 
the wells and the plate was incubated in the dark for 15 min. The reaction was stopped 
using the stop solution provided (1 N hydrochloric acid) and the absorbance values at 
450 nm was measured using a microplate reader (Molecular Devices Inc.). The intensity 
of the yellow color is inversely proportional to the concentration of 8oxodG in the sample 
or standard. The 8oxodG standard curve was used to determine the amount of 8oxodG 
lesions on the +8oxodG and -8oxodG DNA. 
Titration of the Amount of Streptavidin-Coated Magnetic Beads to use in the BER Assay 
The Dynabeads®M-270 Streptavidin (Invitrogen) were washed and prepared for 
binding according to the manufacturer's instructions. The double-stranded control DNA 
(100 ng) was mixed with the beads (10 ug, 50 ug, 100 ug, 150 ug) and incubated 
according to the manufacturer's instructions. Briefly, the DNA and the beads were 
mixed in a solution containing a final concentration of 5 mM Tris-HCl (pH 7.5), 0.5 mM 
EDTA and 1 M NaCl (IX Binding and Washing [B&W] buffer) and incubated at room 
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temperature for 15 min. The tube was tapped every 3 min to resuspend the beads. At the 
end of the incubation, the tubes were placed on a magnetic stand (Promega) for 2 min and 
the supernatant was removed and discarded. The beads were then washed twice in the 
IX B&W buffer. The beads (containing the bound, double-stranded control DNA) were 
then resuspended in 25 jul of 0.1 M sodium hydroxide (NaOH) to denature the 
double-stranded DNA into single-stranded -8oxodG and biotinylated DNA strands. The 
solution was incubated at room temperature for 5 min (on a shaker). The tube was then 
placed on a magnet for 2 min, after which the supernatant (containing the denatured, 
untagged -8oxodG DNA strands) was collected and stored at 4 °C. A small volume 
(5 JJ.1) of the supernatant eluted from each of the four experiments (10 ug, 50 (ig, 100 u.g, 
150 (ig beads) was electrophoresed on a 12% TBE-poiyacrylamide 8.3 M urea gel as 
described before ("Gel analysis of the single-stranded oligonucleotides" section of this 
chapter). A fixed amount of the -8oxodG DNA strand (11 ng) was also electrophoresed 
to serve as a reference band of known concentration while estimating the amount of DNA 
in the sample lanes. A 10 bp DNA ladder (Integrated Technologies) was also included. 
The intensity of the DNA bands was determined using Image J software vl .37 
(developed by Rasband, 2006). 
Quantification of DNA 
The single-stranded -8oxodG DNA was used to generate a standard curve ranging 
from 0-50 ng/ml (in 10 ng/ml increments). The fluorescent dyes SYBR® Green II 
(Invitrogen) and Quant-iT™ Oligreen ssDNA Reagent (Invitrogen) were diluted 
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according to the manufacturer's instructions. The DNA standards (500 ul) were mixed 
with either of the two diluted dyes (500 ul), incubated at room temperature (in the dark) 
for 5 min, and aliquots (200 ul) were loaded in quadruplicate wells of a black 96-well 
plate. The fluorescence was recorded using a fluorescence plate reader at the 
excitation/emission wavelengths of 497 nm/520 nm and 480 nm/520 nm for the SYBR® 
Green II and Quant-iT™ Oligreen dyes respectively. 
Cell Lines and Media 
SUM149PT cells were cultured in Ham's F12 media supplemented with 
10% (vol/vol) FBS, IX P/S/F, 5 ug/ml insulin, 1 ug/ml hydrocortisone and 
10 mM HEPES. MCF7 cells were cultured in media containing DMEM, 10% FBS and 
IX P/S/F. All the cells were maintained in 5% C02 at 37 °C. 
Selection of a Suitable Transfection Reagent 
Transfection. SUM149PT cells were plated (1 x 105 cells per well) on a 24-well plate 
using 500 ul of regular growth media, and allowed to adhere overnight. Double-stranded 
control DNA (800 ng) was transfected into each well using either Lipofectamine™ 2000 
(2 ul/well) (Invitrogen) or Oligofectamine™ (2 ul/well) (Invitrogen) transfection reagent, 
according to the manufacturer's instructions. In order to monitor cell death from 
treatment with the transfection reagents, untransfected cell controls that were treated only 
with either of the two reagents were prepared. The cells were incubated for 4 hr at 37 °C 
in a CO2 incubator. 
43 
Cell lysis, DNA capture, denaturation, and quantification following transfection. 
Following transfection of the control DNA and incubation for 4 hr, the cells were 
trypsinized, quenched using regular growth media and centrifuged at 1500 rpm for 5 min. 
The cell pellet was washed once in 500 ul of IX PBS. The pellet was then resuspended 
in 20 ul of cell lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, and 1% Triton-X 100). Protease inhibitor cocktail (IX) (Sigma Aldrich 
P8340) was added to the lysis buffer prior to use. The cells were rotated at 4 °C for 1 hr 
and centrifuged at 14,000 rpm for 10 min (Hou, Prasad, Asagoshi, Masaoka, & Wilson, 
2007). The supernatant was removed and stored at -20 °C until future use. 
The Dynabeads® M-270 Streptavidin (Invitrogen) were washed and prepared for 
binding according to the manufacturer's instructions. The cell lysate was thawed on ice 
prior to use. The NaCl and EDTA concentrations in the lysate were adjusted prior to the 
addition of streptavidin-coated magnetic beads, to facilitate bead binding. The 
recommended bead binding conditions are 5 mM Tris HC1 (pH 7.5), 0.5 mM EDTA, and 
1 M NaCl (Invitrogen). The beads (850 ug) were then added to the cell lysate, incubated 
to allow for DNA capture, and washed, according to the manufacturer's instructions. The 
DNA bound to the beads was then denatured using 0.1 M NaOH and the supernatant was 
collected as described before ("Bead titration" section of this chapter). The DNA 
recovered in the supernatant was then quantified using the Quant-iT™ OliGreen® 
ssDNA reagent (Invitrogen), as described before ("DNA quantification" section of this 
chapter). 
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Transfection of Control and Substrate DNA into SUM149PT and MCF7 cells, DNA 
Capture and Denaturation 
SUM149PT and MCF7 cells were plated as described before ("Selection of a 
transfection agent" section of this chapter). The cells were transfected with the 
double-stranded control DNA (800 ng) or the substrate DNA (800 ng), using 
Lipofectamine™ 2000 (2 ul/well) (Invitrogen) according to the manufacturer's 
instructions. Following incubation for 4 hr at 37 °C, the cells were collected, lysed and 
the transfected DNA was captured and denatured as described before ("Selection of a 
transfection agent" section of this chapter). 
Gel Analysis of DNA Recovered following Capture and Denaturation 
The supernatant containing the DNA recovered following denaturation of the 
captured DNA was heated at 90 °C for 5 min in an 80% (vol/vol) formamide loading 
buffer (Teknova) and immediately loaded on a 12% TBE-polyacrylamide 8.3 M urea gel. 
The gel was run at 12 W for around 30 min, after which it was stained with SYBRR 
Green II (Invitrogen) according to manufacturer's instructions. The DNA bands were 
visualized using 300 nm UV illumination. A 10 bp DNA ladder (Integrated 
Technologies) was also included. 
Preparation and Gel Analysis of Untransfected SUM149PT Cell Controls 
SUM149PT cells were plated in two wells of a 24-well plate as described before 
("Selection of a transfection agent" section of this chapter). Both wells of cells were 
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treated with Lipofectamine ™ 2000 (2 ul/well) according to manufacturer's instructions, 
and incubated for 4 hr at 37 °C in a CO2 incubator. Cells from both the wells were lysed, 
and the lysate from only one well of cells was subjected to bead capture and denaturation 
as described before ("Selection of a transfection agent" section of this chapter). The 
supernatant obtained following denaturation, along with the lysate from the other batch 
of SUM149PT cells were electrophoresed on a 12% polyacrylamide 8.3 M urea gel at 
110 V. The electrophoresed DNA bands were stained using SYBR® Green II, and 
visualized using 300 nm UV illumination. A 10 bp DNA ladder (Integrated 
Technologies) was also included. 
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Results 
Substrate and Control DNA Oligonucleotides 
The 8oxodG BER assay uses a double-stranded oligonucleotide DNA substrate 
(also represented as "+ 8oxodG/biotinylated DNA") that consists of a biotinylated DNA 
strand (nontarget strand) that is base paired to an untagged DNA strand containing a 
single 8oxodG lesion (+8oxodG or target strand). A double-stranded control DNA (also 
represented as "- 8oxodG/biotinylated DNA") that is identical to the substrate DNA, 
except that it has a guanine instead of the 8oxodG lesion on the untagged strand 
(-8oxodG or control strand), was used for the optimization experiments. 
Overview of the in vivo 8oxodG BER Assay 
In the first step, the substrate DNA is transfected into target cells and incubated 
for an increasing period of time to allow repair of the 8oxodG lesion. The cells are then 
lysed and the biotinylated substrate DNA is captured using streptavidin-coated magnetic 
beads. In the presence of a magnet, the strand containing the 8oxodG lesion (+8oxodG or 
target strand) is denatured and isolated from the streptavidin-bound biotinylated strand 
(nontarget strand). The isolated DNA is then quantified and subjected to an 8oxodG 
competitive ELISA to measure the disappearance of 8oxodG lesions over time (Figure 7). 
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Figure 7. Overview of the in vivo 8oxodG BER assay 
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Gel Analysis of the Single-Stranded DNA Oligonucleotides 
In order to verify the lengths of the synthesized single-stranded DNA 
oligonucleotides, and to establish the experimental conditions for the denaturing gel 
electrophoresis, the +8oxodG, -8oxodG and biotinylated DNA oligonucleotides were 
electrophoresed on a denaturing gel (Figure 8) prior to being used for preparation of the 
substrate and control DNA. 
Lanes 
Bp 
60 
50 
40 
30 
25 
20 
15 
10 
•*—- Biotinylated DNA 
strand 
*—- -SoxodG or +SoxodG DNA 
strands 
Figure 8. Gel analysis of the single-stranded DNA oligonucleotides used in the in vivo 
8oxodG BER assay. The single-stranded -8oxodG, +8oxodG and biotinylated DNA 
oligonucleotides (50 ng) were denatured by heating at 90 °C for 5 min in 95% (vol/vol) 
formamide. The samples were loaded on a 15% TBE-polyacrylamide 7 M urea gel, 
stained using SYBRR Green II and visualized using 300 nm UV illumination. 
Lane 1: 10 bp DNA ladder; lane 2: -8oxodG DNA strand; lane 3: +8oxodG DNA strand; 
lane 4: biotinylated DNA strand. 
On electrophoresis, the 24-mer -8oxodG DNA (lane 2) and +8oxodG DNA (lane 
3) oligonucleotides were found to comigrate with and slightly above a 25-mer DNA 
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marker, respectively. We believe that the +8oxodG strand migrated slower than expected 
due to the presence of the 8oxodG lesion. Besides the 24-mer band, a faint band which 
was around 50 bases in length was also observed in the -8oxodG DNA lane. This was 
probably formed due to the self-annealing of the 24-mer -8oxodG DNA strands, since the 
DNA has self-complementary regions of guanine and cytosine bases. The 28-mer 
biotinylated DNA strand (lane 3) was found to migrate slightly above a 30-mer DNA 
marker. The slower migration was probably due to the presence of the biotin tag. Both 
the +8oxodG and biotinylated DNA were found to stain less strongly with the SYBRK 
Green II dye when compared to the -8oxodG DNA. Due to their high tendency to donate 
electrons, guanine bases have been shown to be efficient fluorescence quenchers 
(Lacowicz, 2006). The 8oxodG bases have an oxidation potential that is approximately 
0.5 V lower than that of guanine (Stover, Ciobanu, Cliffel, & Rizzo, 2007). Thus, we 
believe that the low oxidation potential of the 8oxodG lesion in the +8oxodG DNA may 
quench the fluorescence of the dye. We also speculate that the presence of the biotin tag 
in the biotinylated DNA reduces the surface adsorption of the monomeric dye to the 
DNA. 
Preparation of Substrate and Control DNA 
The substrate and control DNA were prepared by annealing the single-stranded 
+8oxodG and -8oxodG oligonucleotides respectively to the biotinylated DNA 
oligonucleotide in a 2:1 ratio. This ratio was used to ensure the annealing of all the 
biotinylated DNA strands, so that they would not compete with the annealed substrate or 
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control DNA for binding to the streptavidin-coated beads during the optimization 
experiments. The annealed substrate and control DNA were quantified using SYBR® 
Green I, since this dye binds preferentially to the minor groove of double-stranded DNA 
(Zipper, Brunner, Bernhagen, & Vitzthum, 2004). Following annealing, the DNA was 
analyzed on a 15% nondenaturing polyacrylamide gel (Figure 9). 
Lanes 
Bp 
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• - = Annealed control or 
substrate DNA 
Self-annealed -SoxodiG or 
+80X0dG DNA 
Figure 9. Gel analysis of the annealed double-stranded substrate and control DNA. The 
annealed substrate and control DNA (25 ng each) were electrophoresed on a 
15% TBE-polyacrylamide gel. The gel was stained using SYBR® Green I and visualized 
using 300 nm UV illumination. Lane 1: 10 bp DNA ladder; lane 2: annealed control ds 
DNA; lane 3: annealed substrate ds DNA. ds = double-stranded 
Following annealing, we would expect three species of DNA on the 
nondenaturing gel: (a) the annealed double-stranded substrate or control DNA, 
(b) self-annealed (-24 bp) +8oxodG or -8oxodG DNA (since this was used in excess of 
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the biotinylated DNA for the annealing), and (c) self-annealed (-28 bp) biotinylated 
DNA (if annealing was not 100%). Two bands were seen in both the annealed substrate 
and control DNA lanes; one band was approximately 24 bp in length and the other was 
approximately 45 bp in length. We believe that the 24 bp band corresponds to the 
self-annealed +8oxodG or -8oxodG DNA, and the 45 bp band corresponds to the 
annealed substrate or control DNA. No band approximately 28 bases in length 
(corresponding to self-annealed biotinylated DNA) was observed in the gel. This 
suggests that either all the biotinylated DNA was annealed (which would then suggest 
that the annealing was 100% successful), or the amount of biotinylated DNA in the gel 
was below the limit of sensitivity of the SYBR® Green I dye. In the future, it may be 
useful to determine the extent of annealing by monitoring the hyperchromicity shift at 
260 nm. 
Specificity of the 8oxodG Competitive ELISA 
Since the HT 8oxodG ELISA Kit (Trevigen) was originally developed for the 
quantification of 8oxodG lesions in urine and serum samples, the specificity and 
efficiency of the ELISA when used with the oligonucleotides in our BER assay was first 
evaluated. Specificity of the 8oxodG ELISA may be defined as its ability to discriminate 
between DNA containing 8oxodG lesions and DNA lacking the lesions. Thus, in order to 
monitor ELISA specificity, the single-stranded +8oxodG DNA containing the 8oxodG 
lesion and the -8oxodG DNA lacking the lesion were used as positive and negative 
controls respectively. 
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In order to determine the amount of +8oxodG and -8oxodG DNA to be used for 
monitoring specificity, we first had to determine the range of DNA concentrations that 
could be used with the 8oxodG ELISA, so that the 8oxodG levels quantified are within 
the detection range of the ELISA. The preestablished sensitivity of the 8oxodG ELISA 
was 1.9 ng of 8oxodG/ml, and its detection range was 1.875-60 ng of 8oxodG/ml 
(Trevigen). Thus, the 8oxodG detection range in the 50 ul assay volume (per well) was 
between 0.09375-3 ng of 8oxodG lesions. We calculated that 1 ng of our +8oxodG DNA 
had 0.04683 ng of 8oxodG lesions. Thus, the range of+8oxodG DNA that may be used 
in the 8oxodG ELISA was between 2-64 ng/well. To determine the specificity of the 
ELISA and to optimize its conditions, from this range, we used 5 ng/well of+8oxodG 
and -8oxodG DNA oligonucleotides. This was chosen to minimize the amount of DNA 
to be used in the BER assay. The specificity of the ELISA was measured as the 
difference in absorbance values (AOD450) obtained for equal amounts of+8oxodG and 
-8oxodG DNA. The higher the specificity of the assay the greater the difference in 
absorbance values between the two DNA. 
First, the specificity of the ELISA was monitored in the presence of two blocking 
agents: FBS (2% and 10% [vol/vol]) and BSA (1% [wt/vol]) (Figure 10A). Incubation of 
the wells with 2% FBS (150 ul/well) for 1 hr at 37 °C gave the highest specificity 
(AOD450 = 0.26). Second, in order to identify the optimal concentration of anti-8oxodG 
antibody, the specificity of the ELISA was monitored at increasing (1/250, 1/500, 1/1000, 
1/2000) primary antibody dilutions (Figure 10B). A 1/250 dilution of the primary 
antibody gave the highest specificity (AOD450 = 0.33). Third, to determine the optimal 
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incubation temperature following the addition of the anti-8oxodG antibody to the 
+8oxodG or -8oxodG DNA in the wells, the specificity of the ELISA was monitored at 
different incubation temperatures (25 °C and 37 °C) (Figure IOC). Room temperature 
incubation gave higher specificity when compared to that at 37 °C (AOD450 = 0.33). 
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Figure 10. Specificity of the 8oxodG ELISA at different assay conditions. The 
+8oxodG and -8oxodG DNA (5 ng each) were subjected to the 8oxodG ELISA after 
blocking the wells (A) with either 2% FBS, 10% FBS or 1% BSA for 1 hr at 37 °C, or at 
different dilutions of the anti~8oxodG antibody (B), or using different temperatures for 
incubation of the anti-8oxodG antibody with the single-stranded +8oxodG or -8oxodG 
DNA (C). The specificity was measured as the difference in end absorbance values 
(AOD450) obtained by subtracting the OD450 values of + 8oxodG DNA from those of 
the -8oxodG DNA. The higher the assay specificity, the greater will be the difference in 
absorbance values between the two DNA. The vertical lines depict the standard 
deviation. The bars lacking vertical lines represent the means for which the standard 
deviation was zero. 
Efficiency of the 8oxodG Competitive ELISA 
The efficiency of the 8oxodG ELISA was determined using the optimal assay 
conditions established in previous experiments (Figure 10 A, B, C). The amount of 
8oxodG lesions quantified in 5 ng of+8oxodG DNA from two independent experiments 
(done using two different ELISA plates) were 0.1187 ng and 0.0982 ng of 8oxodG 
lesions. The average amount of 8oxodG lesions determined for the two experiments was 
0.1085 ng lesions. The standard curve and sample absorbance values from one 
representative experiment have been shown in Figure 11. The figure also shows that the 
u.^o 
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average absorbance for the -8oxodG DNA strand was near that observed for the 0 n 
standard. 
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c. 
Samples Average absorbance 
(OD 450 nm) 
-8oxodGDNA 1.650 
+8oxodGDNA 1.342 
Concentration of 8oxodG lesions in 
5 ng of+8oxodG DNA = 2.375 ng/ml 
Figure 11. Efficiency of the 8oxodG competitive ELISA. The standard curve (A), 
average absorbance (OD450) values of the standards (B), and average OD450 values of 
the -8oxodG DNA (5 ng) and +8oxodG DNA (5 ng) (C) are shown. The concentration of 
8oxodG lesions in the +8oxodG DNA was determined using the standard curve. The 
results shown are representative of two independent experiments. 
We had previously calculated that 0.04683 ng of 8oxodG lesions are present in 
1 ng of +8oxodG DNA. Thus, we theoretically expected 0.2342 ng of 8oxodG lesions in 
5 ng of the +8oxodG DNA. Since the ELISA detected only 0.1085 ng of the lesions in 
5 ng of the +8oxodG DNA, its efficiency was approximately 46.33%. 
Once the efficiency was determined, the range of+8oxodG DNA concentrations 
that could be used with the 8oxodG ELISA was recalculated; the theoretical amount of 
+8oxodG DNA that may be used after correction for ELISA efficiency is 4.3-138.4 
ng/well. 
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In vitro Validation of the 8oxodG Competitive ELISA for Use in the BER Assay 
At the end of the capture and denaturation step in the BER assay, the supernatant 
isolated is likely to have the following DNA species: repaired +8oxodG DNA strands (no 
8oxodG lesions), and unrepaired +8oxodG DNA strands (with 8oxodG lesions). 
Depending on the efficiency of BER in the target cells, the ratio of repaired to unrepaired 
+8oxodG DNA may range from 1:0 to 0:1. We wanted to see if the 8oxodG ELISA was 
capable of effectively measuring 8oxodG lesions in the unrepaired DNA, against a 
background of repaired DNA. Thus, we attempted to simulate the outcome of the BER 
assay in order to validate the 8oxodG ELISA for use with the assay. 
In this experiment, the -8oxodG DNA strand was used to represent repaired DNA 
and the +8oxodG DNA strand was used to represent the unrepaired DNA. The -8oxodG 
DNA strands were spiked with an increasing amount of+8oxodG DNA, while keeping 
the total amount of DNA constant (100 ng) (Table 2). The amounts of+8oxodG DNA 
used were within the theoretical detection range of the ELISA (4.3-138.4 ng/well). The 
ability of the ELISA to detect increasing amounts of 8oxodG lesions in the +8oxodG 
DNA (unrepaired DNA) against a background of-8oxodG DNA (repaired DNA) was 
then determined (Figure 12). 
The 8oxodG ELISA showed the ability to detect and quantify 8oxodG lesions on 
the +8oxodG DNA in a dose-dependent manner, in the presence of different amounts of 
-8oxodG DNA. This suggests that the presence of the repaired DNA will not interfere 
with the quantification of lesions on the unrepaired DNA (at least when the total amount 
of repaired and unrepaired DNA together is < 100 ng). Thus, the 8oxodG ELISA may be 
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used in the BER assay to measure the decrease in the amount of 8oxodG lesions on the 
+8oxodG DNA, seen with time. This experiment may be used in the future to generate a 
standard curve to estimate the amount of repaired versus unrepaired target DNA 
recovered from the target cells. 
Table 2 
Amount of+8oxodG and -8oxodG DNA used for the in vitro validation of the 8oxodG 
ELISA 
Amount of +8oxodG DNA Amount of -8oxodG DNA Total amount of 
per well (ng) per well (ng) DNA per well (ng) 
0 
6.25 
12.5 
25 
50 
100 
100 
93.75 
87.5 
75 
50 
100 
100 
100 
100 
100 
100 
100 
Note. An increasing amount of+8oxoG DNA was loaded in triplicate wells of the 
8oxodG ELISA plate. The -8oxodG DNA was added to these wells such that the total 
amount of DNA in each well was 100 ng. The DNA was then subjected to the 8oxodG 
ELISA and the concentration of 8oxodG lesions in each well was determined. 
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Figure 12. Dose-dependent detection of 8oxodG lesions on the +8oxodG DNA in the 
presence of the -8oxodG DNA. The -8oxodG was spiked with an increasing amount of 
+8oxodG (target) DNA so that the final amount of DNA in each well was 100 ng. The 
8oxodG lesions were detected and quantified using the HT 8oxodG ELISA Kit as 
described in the Methods section. The data points represent the mean concentration of 
8oxodG lesions. The vertical lines represent the standard deviation. 
Titration of the Amount ofStreptavidin-Coated Magnetic Beads to Use in the BER Assay 
In the BER assay, following lysis of the cells transfected with the biotin-tagged 
substrate or control DNA, the transfected DNA will have to be captured using 
streptavidin-coated magnetic beads. In order to determine the optimal amount of beads 
required to effectively capture the transfected substrate or control DNA following cell 
lysis, a titration using different bead concentrations was performed. 
Double-stranded control (-8oxodG/biotinylated) DNA (100 ng), and different 
amounts of beads (10 u.g, 50 ug, 100 ug, 150 ug) were used for the titration. Following 
binding of the control DNA to the beads, the DNA was denatured using 0.1 M sodium 
hydroxide, and the supernatant was collected in the presence of a magnet. This step 
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would, in theory, isolate the -8oxodG DNA strand from the biotinylated DNA strand 
bound to the beads. The DNA isolated from each of the four experiments that used 
different amounts of beads were then analyzed on a denaturing gel (Figure 13 A) after 
staining with SYBR® Green II. 
The intensity of the 24-mer DNA bands obtained for the DNA isolated from each 
of the four experiments, and the reference DNA band (11 ng of-8oxodG DNA strand) 
were determined using the Image J software (Figure 13B). The band intensities of the 
samples were then expressed as a percentage of the band intensity of the reference DNA. 
Since the amount of DNA in the reference band was known (11 ng), the amount of DNA 
in each band from the sample lanes (lanes 3-6) was estimated. Using these data, the total 
amount of DNA isolated from each of the four bead capture experiments was estimated 
(Figure 13B). 
The expected amount of isolated single-stranded -8oxodG DNA from 100 ng of 
double-stranded control DNA, following denaturation, was 50 ng. Approximately 
13.98 ng, 20.41 ng, 41.66 ng and 52.05 ng of single-stranded control DNA was isolated 
from 10 ng, 50 ug, 100 ug, and 150 ug of bead-DNA suspension respectively, following 
denaturation. From the titration performed, 150 ug of streptavidin-coated magnetic beads 
was determined to be the optimal amount of beads that could bind 100 ng of substrate or 
control DNA. Thus, the optimal ratio of the amount of substrate or control DNA to the 
amount of streptavidin-coated beads to be used was estimated to be approximately 1 ng 
DNA to 1.5 ug beads. 
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A. 
Lanes 
art* i f f -SoxodG DNA strands 
B. 
Reference Band 
DNA isolated following titration of 
streptavidin-coated magnetic beads 
10 jxg 50 ng 100 [xg 150 [xg 
Band Intensity 
Relative band intensity 
2078 
1 
528 
0.254 
771 
0.371 
1574 
0.757 
1966 
0.946 
Amount of DNA per 
band (ng/5[xl) 
11 2.795 4.081 8.332 .10.407 
Amount of DNA in the 
supernatant (ng/25u.l) 
13.98 20.41 41.66 52.05 
Figure 13. Titration of the amount of streptavidin-coated magnetic beads required to 
capture the control DNA. The control DNA (100 ng) was mixed with streptavidin-coated 
magnetic beads (10 [xg, 50 jxg, 100 u.g, 150 [xg) and incubated as described in the 
Methods section. The DNA captured by the beads was then denatured using 
0.1 M sodium hydroxide in the presence of a magnet, and the DNA in the supernatant 
was isolated. The isolated DNA was analyzed on a 12% TBE-polyacrylamide 8.3 M urea 
gel (A) following denaturation by heating at 90 °C in 95% (vol/vol) formamide. Lane 1: 
10 bp DNA ladder; lane 2: Reference band (-8oxodG DNA strand); lane 3, 4, 5, 6: DNA 
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isolated following capture and denaturation of control DNA using 10 ug, 50 (ig, 100 \xg, 
and 150 \xg beads respectively. The band intensities were determined using Image J 
software (B) and the amount of DNA in each band and in the eluted supernatant was 
calculated from the known amount of DNA in the reference band. 
The gel (Figure 13 A) also showed that only the -8oxodG DNA strand (24-mer) 
and not the biotinylated DNA strand (28-mer) was isolated following bead capture and 
denaturation. Thus, treatment with 0.1 M sodium hydroxide did not disrupt the 
streptavidin-biotin linkages. As seen in Figure 8, an additional band (~40-mer) was seen 
in all the lanes. As mentioned before, it is believed that this band is due to self-annealing 
of the -8oxodG DNA strands. 
Selection of a Suitable Fluorescent Dye for the Quantification of the Isolated DNA in the 
BER assay 
In the BER assay, following capture and denaturation of the transfected substrate 
DNA, the isolated DNA containing the +8oxodG DNA strand will have to be quantified 
prior to being used in the 8oxodG ELISA. Two fluorescent dyes (SYBR® Green II and 
Quant-iT™ Oligreen) were evaluated for their efficiency in quantifying single-stranded 
DNA. The single-stranded -8oxodG DNA was used to generate standards ranging from 
0-50 ng/ml (in 10 ng/ml increments). The R2 values of the standard curve generated 
using the same set of standards and measured using each of the two dyes were then 
compared. The Quant-iT™ Oligreen dye gave better R2 value for the standard curve 
(R2 = 0.9982) when compared to the SYBR® Green II dye (R2 = 0.8877). Similar results 
were obtained when using standards ranging from 0-25 ng/ml (in 5 ng/ml increments); 
the R2 value for the standard curve using Quant-iT™ Oligreen dye and SYBR® Green II 
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dye was 0.9969 and 0.7291 respectively. Thus, the Quant-iT™ Oligreen fluorescent dye 
was chosen for the quantification of the isolated DNA following denaturation in the BER 
assay. 
Transfection of the Substrate or Control DNA into Target Cells 
The first step of the BER assay involves the transfection of the substrate DNA 
into target cells. Since the assay was being developed to confirm the results observed 
from the first part of our study (described in chapter one), we used SUM149PT cells to 
determine conditions for substrate or control DNA transfection. Double-stranded control 
DNA (-8oxodG/biotinylated DNA) was used in the optimization experiments. 
Two different transfection reagents (Lipofectamine™ 2000 and 
Oligofectamine™) were first compared for their efficiency in transfection of the control 
DNA into the target cells. No cytotoxicity was observed among the untransfected cells 
that were treated only with either of the two reagents (2 ul of reagent per well of a 
24-well plate). Since transfection of biotin-tagged oligonucleotides has not been 
reported previously, we decided to use a large amount of control DNA for the 
transfection to first verify if the biotin-tagged DNA can successfully transfect cells. Thus 
800 ng of control DNA was transfected using either of the two reagents (2 ul of reagent 
per well) into SUM149PT cells. Following 4 hr of incubation, the cells were lysed. To 
prevent the denaturation of the biotin moiety in the control DNA, a nonionic 
detergent-based cell lysis buffer was used. Since the optimal ratio of the amount of 
substrate or control DNA to the amount of streptavidin-coated beads was previously 
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determined to be 1 ng DNA to 1.5 fag beads (Figure 13), 850 |j.g of beads were used to 
capture the control DNA (800 ng) from the cell lysate. The captured DNA was then 
denatured in the presence of a magnet, and the DNA recovered in the supernatant was 
quantified using the Quant-iT™ Oligreen dye. The concentration of DNA in the eluted 
supernatant was approximately the same for cells transfected with Lipofectamine™ 2000 
(0.27 ng/ul) and Oligofectamine™ reagent (0.25 ng/|al) (Figure 14). Since 
Lipofectamine™ 2000 is a more commonly used reagent, we decided to use this for 
future experiments. 
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Figure 14. Selection of a suitable transfection reagent for the BER assay. SUM149PT 
cells were transfected with the control DNA (800 ng) using 2 p.l/well of either the 
Lipofectamine™ 2000 or Oligofectamine™ transfection reagent. The cell lysis, capture 
and denaturation steps were performed as described in the Methods section. The DNA 
recovered in the supernatant following denaturation, was quantified using the Quant-iT™ 
Oligreen dye. The bars represent the mean concentrations of DNA recovered from two 
independent experiments. The vertical lines represent standard errors of the means. 
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Following selection of a suitable transfection reagent, the optimal volume of the 
reagent to use for transfection was then determined. Out of three different volumes of 
Lipofectamine™ 2000 tested (2, 4, or 6 ul of reagent per well of a 24-well plate), the 
concentration of the recovered DNA was the highest when 2 ul of Lipofectamine™ 2000 
was used for transfection of SUM149PT cells (Figure 15). No cytotoxicity was observed 
in the transfected cells (with 800 ng control DNA) or untransfected cell controls (treated 
only with 2, 4, or 6 ul of Lipofectamine™ 2000), following incubation for 4 hr at 37 °C. 
This shows that neither the reagent, nor the combination of reagent with DNA were 
cytotoxic to the cells at the concentrations used and the time incubated. 
s. 
z Q 
CD 
o X 
0 00 
1 
0 
c 
.o 43 
ce
n
 
c 
o 
o 
~ rl/6 
c s
-^  
•D 
0) 
0) 
> o 
u 
•a 
c 
(0 
(0 
0.30 -, 
0.25 -
0.20 -
0.15 -
0.10 
0.05 -
n nn \J.\JKJ 
LF2ul LF4ul LF6ul 
Volume of Lipofectamine 2000 
Figure 15. Optimal volume of Lipofectamine™ 2000 for use in the transfection step of 
the BER assay. The SUM149PT cells were transfected with control DNA (800 ng) using 
either 2 ul, 4 ul or 6 ul of Lipofectamine™ 2000. The cell lysis, capture and 
denaturation steps were performed as described in the Methods section. The DNA eluted 
in the supernatant following denaturation was quantified using the Quant-iT™ Oligreen 
dye. LF = Lipofectamine™ 2000. 
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Gel Analysis of the DNA Recovered following Transfection of Substrate or Control DNA 
into SUM149PTandMCF7 Cells 
Following transfection of substrate DNA (+8oxodG/biotinylated DNA) into target 
cells, incubation, cell lysis, bead capture and denaturation in the presence of a magnet, 
the recovered DNA should only consist of the +8oxodG DNA strand (Figure 7). To 
confirm that the DNA recovered following transfection of the substrate DNA into 
SUM149PT cells consisted only of the +8oxodG DNA strands, the transfection was 
performed in SUM149PT cells using substrate DNA (800 ng) and Lipofectamine™ 2000. 
In addition, another batch of SUM149PT cells was transfected with the control DNA 
(800 ng) instead of the substrate DNA. Following incubation for 4 hr, and cell lysis, the 
transfected substrate and control DNA were captured, denatured, and the supernatant was 
collected in the presence of a magnet. Equal volumes of the supernatant from each 
transfection were electrophoresed on a denaturing gel (Figure 16A, lanes 2, 3). The gel 
showed one band that corresponds to the 28-mer biotinylated DNA and another band that 
corresponds to the 24-mer +8oxodG or -8oxodG DNA. Both the bands were observed in 
the DNA recovered following transfection of the control DNA (Fig 16A, lane 2) and the 
substrate DNA (Fig 16A, lane 3) into SUM149PT cells. In addition to these two bands, a 
third band, approximately 50 bases in length, was seen only in the DNA recovered 
following transfection of the control DNA (Fig 16 A, lane 2). We speculated that this 
50-mer was formed due to self-annealing of the -8oxodG DNA strands, as was previously 
observed on gel electrophoresis of single-stranded -8oxodG DNA (Figure 8). The 
absence of this 50-mer band in the DNA recovered following transfection of the substrate 
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DNA (Fig 16A, lane 3) is also consistent with the observations from electrophoresis of 
the single-stranded +8oxodG DNA in Figure 8. 
The substrate and control DNA were also transfected into another cell line 
(MCF7), to show that the bands observed were not cell-type specific and to also 
demonstrate that the substrate or control DNA could be transfected into other cell lines. 
Following gel electrophoresis, the DNA recovered following transfection of the control 
DNA (Figure 16A, lane 4) and the substrate DNA (Figure 16A, lane 5) into MCF7 cells 
produced bands identical to those observed from the transfections in the SUM149PT cells 
(Figure 16A, lanes 2, 3). 
To further confirm that the DNA bands observed in Figure 16A were specific for 
the transfected DNA, we prepared two sets of untransfected SUM149PT cells. Both sets 
of cells were lysed. The lysate from one set of cells, on electrophoresis, showed a smear 
of DNA (Figure 16B, lane 2). No bands corresponding to the substrate or control DNA 
(24, 28 bases) were seen. The lysate from the other set of untransfected SUM149PT cells 
was subjected to bead capture and denaturation. On electrophoresis of the denatured 
supernatant, no bands were observed (Figure 16B, lane 3). Nanodrop spectrophotometry 
of this denatured supernatant also confirmed the absence of DNA (data not shown). This 
suggested that no DNA was isolated on subjecting the untransfected SUM149PT cells to 
lysis, bead capture and denaturation. Taken together with the data obtained in Figure 
16A, we concluded that the DNA recovered from the cell lysates of SUM149PT and 
MCF7 cells transfected with the substrate and control DNA consisted only of the 
transfected DNA. 
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Figure 16. Transfection of control and substrate DNA into SUM149PT and MCF7 cells. 
SUM149PT and MCF7 cells were transfected with the control or substrate DNA (800 ng) 
using Lipofectamine™ 2000 (A). The cell lysis, capture and denaturation steps were 
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performed as described in the Methods section. The DNA eluted in the supernatant was 
run on a 12% polyacrylamide 8.3 M urea gel. Lane 1: 10 bp DNA ladder; lanes 2, 3: 
DNA recovered following transfection of SUM149PT cells with control DNA and 
substrate DNA respectively; lanes 4, 5: DNA recovered following transfection of MCF7 
cells with control DNA and substrate DNA respectively. Cell lysates from untransfected 
SUM149PT cells (B) were either used as is (Panel B, lane 2), or subjected to bead capture 
and denaturation (Panel B, lane 3), prior to being electrophoresed. A 10 bp DNA ladder 
(Panel B, lane 1) is also shown. 
Consequences of the Coelution of the Biotinylated DNA Strand with the +8oxodG or 
SoxodG DNA strand following Denaturation of Captured Substrate or Control DNA 
Figure 16A showed that the +8oxodG or -8oxodG DNA strand (24-mer) and the 
biotinylated DNA strand (28-mer) were present in the supernatant following bead capture 
of transfected DNA and denaturation. The presence of the biotinylated DNA strand in 
the supernatant was unexpected since we had previously observed that when using 
similar bead capture and denaturation conditions, the biotinylated strand did not coelute 
with the +8oxodG or -8oxodG DNA strand (Figure 13). Figure 16A also showed that the 
amount of biotinylated DNA that coeluted with the +8oxodG or -8oxodG DNA strands in 
each of the four transfection experiments (Figure 16A, lanes 2-5) was consistent (as 
visualized by the band intensity). This suggested that as long as the DNA capture, 
denaturation and recovery steps are consistently performed following every transfection 
experiment, the percentage of coeluted biotinylated DNA (if any) that is recovered from 
every experiment would be similar. Thus, if the presence of the biotinylated DNA did 
not compromise the efficiency of the 8oxodG ELISA to quantify lesions on the +8oxodG 
DNA, its coelution may be overlooked. To verify this, the ability of the ELISA to detect 
and quantify 8oxodG lesions on increasing amounts of+8xodG DNA, in the 
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absence/presence of an equal amount of the biotinylated DNA was monitored (Table 3, 
Figure 17). 
Table 3 
Amount of biotinylated DNA and/or +8oxodG DNA used to determine the efficiency of 
the 8oxodG ELISA 
A. B. 
Amount of+8oxodG Amount of+8oxodG Amount of biotinylated 
DNA per well (ng) DNA per well (ng) DNA per well (ng) 
0 
6.25 
12.5 
25 
50 
100 
0 
6.25 
12.5 
25 
50 
100 
0 
6.25 
12.5 
25 
50 
100 
Note. An increasing amount of+8oxodG DNA was loaded in triplicate wells of the 
8oxodG ELISA plate (A). An increasing amount of+8oxodG DNA spiked with an equal 
amount of biotinylated DNA was also loaded in triplicate wells of the 8oxodG ELISA 
plate (B). The DNA was then subjected to the 8oxodG ELISA and the concentration of 
8oxodG lesions in each well was determined. 
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Figure 17. Quantification of 8oxodG lesions on the +8oxodG DNA in the presence or 
absence of the biotinylated DNA. Increasing amounts of +8oxodG (target) DNA strand 
were subjected to the 8oxodG ELISA with or without equal amounts of biotinylated 
DNA strand. The concentration of 8oxodG lesions on the +8oxodG DNA strand in the 
absence (black diamonds, black trendline) or presence (red squares, red trendline) of the 
biotinylated DNA strand was then determined. 
The slopes of the trend lines (Figure 17) obtained for the concentration of 8oxodG 
lesions on increasing amounts of +8oxodG DNA were similar in both the absence 
(slope = 0.186) and presence (slope = 0.181) of biotinylated DNA. Thus, the presence of 
the biotinylated DNA does not interfere with the quantification of 8oxodG lesions on the 
+8oxodG DNA strand and hence its coelution following capture and denaturation of the 
substrate DNA may be overlooked. 
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Discussion 
Defects in the BER of 8oxodG lesions have been implicated in cancer (Paz-Elizur 
et al., 2003). The efficiency of BER of 8oxodG lesions in mammalian cells may be 
determined by monitoring the disappearance of 8oxodG levels in cellular DNA, 
following treatment with oxidizing agents. Techniques such as comet assays, 
immunoassays and HPLC-ECD that have been developed for this purpose suffer from 
issues related to their sensitivity, specificity and artifact production. Besides the HCR 
assay, currently, no other reliable assay to measure in vivo BER of 8oxodG lesions using 
DNA repair substrates is available. Thus, in this study, we have designed a novel in vivo 
assay for measuring BER of 8oxodG lesions using an oligonucleotide DNA substrate. 
This assay provides an advantage over the HCR assay because it detects the kinetics of 
BER, whereas the HCR assay is an end-point assay. 
The double-stranded oligonucleotide DNA substrate used in our BER assay 
consists of an 8oxodG lesion on one strand and a 3' biotin tag on the complementary 
strand. The substrate DNA is transfected into target cells using Lipofectamine™ 2000 
and incubated for an increasing period of time to allow for repair. The cells are then 
lysed using a nonionic cell lysis buffer and the lysate is treated with streptavidin-coated 
magnetic beads (DNA [ng]: bead [ug] ratio = 1:1.5), to allow the biotin-tagged substrate 
DNA to be captured from the cell lysate. Following DNA capture and washing to 
remove nonspecific DNA binding to the beads, the bead bound DNA is treated with 
0.1 M sodium hydroxide to denature the untagged target strand from the biotin-tagged 
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nontarget strand (still bound to the beads). In the presence of a magnet, the bead bound 
nontarget strand is separated from the denatured target strands (in the supernatant). The 
DNA in the supernatant is then quantified by fluorimetry using the Quant-iT™ Oligreen 
fluorescent dye. Equal amounts of DNA from each time-point (the various time-points at 
which the target cells were incubated) are then subjected to an 8oxodG competitive 
ELISA, to quantify the amount of 8oxodG lesions on the target DNA. In vivo BER is 
measured as the disappearance of 8oxodG lesions with time. 
The substrate DNA is a critical component of any repair assay. Thus, we first 
generated a list of specifications for selection of a suitable substrate DNA for our assay. 
Being an in vivo assay, the substrate DNA has to be transfected into cells. Thus, the 
substrate DNA should be double-stranded, with one or more 8oxodG lesions at 
predetermined position(s). It should also be easy to transfect into cells and be stable in 
vivo. Since the recognition of the lesions by hOGGl followed by hOGGl- or 
APE 1-mediated cleavage is a critical step in BER, the biochemistry of the substrate DNA 
chosen should not interfere with these steps. Following cell lysis, the DNA should be 
easily captured and purified, and form well characterized bands after gel electrophoresis. 
As a first step, to make the choice between plasmid and linear oligonucleotide 
substrates, the advantages and disadvantages of each substrate in relevance to this assay 
were analyzed. Plasmid substrates can be transfected using common lipid-based reagents 
and are stable in vivo. In addition, plasmid substrates allow analysis of the long-patch 
BER (LP-BER) of base lesions, because the clamp protein proliferating cell-nuclear 
antigen (PCNA) required for LP-BER, functions only on circular DNA substrates (Biade, 
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Sobol, Wilson, & Matsumoto, 1998). On the other hand, the preparation and purification 
of plasmid DNA substrates containing 8oxodG lesions at predetermined positions 
(described by Hou, Prasad, Asagoshi, Masaoka & Wilson, 2007) is tedious. In addition, 
genomic DNA contamination may be introduced during the isolation of the plasmids 
from the cell lysate, following transfection and incubation in target cells. 
Linear oligonucleotide DNA substrates on the other hand can be annealed from 
single-stranded commercially synthesized and purified strands. If tagged, the 
oligonucleotide DNA substrate can be easily captured and purified following cell lysis, 
without disrupting the 8oxodG lesions. However, the disadvantages of these substrates 
are that they do not allow repair using the LP-BER pathway, and their stability may be 
compromised in vivo. Studies conducted in vitro have shown that hOGGl-mediated 
repair of 8oxodG occurs almost exclusively along the short- patch BER (SP-BER) 
pathway (Dianov et. al., 1998; Fortini et. al., 2003). Thus, the use of a linear 
oligonucleotide DNA substrate to measure BER of 8oxodG lesions should not pose a 
problem. In addition, partially phosphorothionated substrate DNA may be used to 
maintain in vivo substrate stability. Thus, we decided to use a linear oligonucleotide 
DNA substrate for our BER assay. 
The successful hOGGl-mediated incision of a commercially available (Trevigen) 
oligonucleotide, 24 bases in length, carrying a single 8oxodG lesion, has been shown 
before (Achanta & Huang, 2004). The study also used a 3' biotin tagged oligonucleotide 
that was complementary to the 8oxodG containing strand. Thus, the two oligonucleotides 
described by Achanta and Huang (2004), were chosen for our assay. To prevent 
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interference with enzyme binding and excision of the 8oxodG lesion on the target strand, 
the biotin moiety was tagged only to the complementary strand. 
Denaturing gel electrophoresis of the purchased single stranded DNA 
oligonucleotides revealed bands of the expected sizes for the single-stranded +8oxodG 
DNA and biotinylated DNA (Figure 8). However, for the single-stranded -8oxodG DNA, 
besides a 24 base fragment, another fragment which was approximately 50 bases in 
length was observed. Although the +8oxodG DNA had the same sequence as the 
-8oxodG DNA plus an 8oxodG lesion, the 50-mer DNA band was not observed in the 
+8oxodG DNA lane. We speculated that this additional band was formed due to 
self-annealing of the -8oxodG DNA strands, and that this was not seen with the +8oxodG 
DNA strands because the 8oxodG lesion destabilized and thus prevented self-annealing. 
To test this hypothesis, we treated the -8oxodG DNA with higher formamide 
concentrations (98-100% [vol/vol]) to completely disrupt self-annealing, and 
electrophoresed the DNA in a denaturing gel. Following staining, the additional 50 base 
length band was not observed (data not shown). However, when this experiment was 
repeated, the band reappeared (data not shown). In the future, the identity of the 
fragment may be confirmed by excision of the band, elution of the DNA and sequencing. 
Transfection of deoxyribonucleotides into cell cultures has been previously 
performed (Li, Dowbenko, & Lasky, 2002). However, no study to date has transfected 
biotin-tagged oligonucleotides into cell cultures. Thus, we first had to verify if the 
biotin-tagged substrate DNA could successfully be transfected into target cells. The 
double-stranded control DNA was used to optimize conditions for transfection because it 
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was identical to the substrate DNA, except for the absence of an 8oxodG lesion. The 
control DNA was transfected into SUM149PT cells using two different lipid-based 
transfectants. At the end of cell lysis, capture of the transfected DNA, and denaturation, 
the supernatant was collected and subjected to DNA quantification by fluorimetry. The 
analysis showed the presence of DNA in the supernatant (Figure 14). However, the 
species of DNA in the supernatant could not be verified by gel electrophoresis because 
the amount of DNA recovered was low. The transfection was then repeated in 
SUM149PT cells (with both control and substrate DNA), and this time the entire volume 
of supernatant isolated following bead capture of the lysate and denaturation was 
electrophoresed on a denaturing gel, to visualize the DNA recovered. The gel showed the 
presence of the DNA bands that corresponded to those of the substrate and control DNA 
(Figure 16A). The same results were obtained when the experiment was repeated using 
another cell line (MCF7). The use of two untransfected SUM149PT cell controls 
confirmed that the DNA bands observed were not endogenous to the cell lysate (Figure 
16B). Taken together, these results confirmed that the biotin-tagged substrate and control 
DNA could indeed be transfected into cell cultures. 
Although we did observe transfection of the substrate and control DNA, the 
percentage of transfected DNA recovered following cell lysis, capture and denaturation 
was low (-2.03%). This may be due to a number of reasons; failure of the 
oligonucleotide DNA substrate to enter the cells, their susceptibility to cytoplasmic, 
lysosomal, or other organellar DNases, the exocytosis of the DNA, or the loss of DNA 
during cell division (Lechardeur et al., 1999). To circumvent digestion by cellular 
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endo- and exonucleases, some of the phosphate groups in the oligonucleotide substrate 
may be modified by phosphorothioation in future experiments. It is however important 
not to modify phosphates that flank the 8oxodG lesion, so that the hOGGl- or 
APE 1 -mediated strand cleavage and other BER steps may proceed unhindered. It may 
also be useful to optimize the volume of cell lysis buffer used to lyse the cells following 
transfection, to ensure the release of transfected DNA from all the cells. It has been 
shown with plasmid DNA that the use of peptide scaffolds containing cationic peptides 
(which bind to the DNA) conjugated to a nonclassical nuclear localization sequence 
(NLS), greatly improves nuclear import and transfection efficiency (Subramanian, 
Ranganathan, & Diamond, 1999). These peptide scaffolds are commercially available as 
the reagent Nupherin™ (Biomol). In the future, the ability of this reagent to improve 
transfection of the substrate DNA, and to specifically target the DNA to the nucleus to 
monitor nuclear BER, may be investigated. 
An unexpected observation from the transfection of control and substrate DNA 
was the coelution of the biotinylated DNA strand with the +8oxodG or -8oxodG DNA 
strand, following capture and denaturation (Figure 16A). This was however not observed 
during preliminary analysis of the bead capture and denaturation steps using the control 
DNA (Figure 13). We speculate that this may be due to the partial denaturation of the 
biotin moiety during repeated freeze-thaw of the control and substrate DNA for use in the 
optimization experiments. This may compromise the ability of the biotin-tagged 
substrate to bind strongly to the streptavidin-coated beads, thereby resulting in its elution 
following treatment with 0.1 M sodium hydroxide. If this were the case, then some of the 
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biotin-tagged substrate may have also been lost during the wash steps, which would then 
account for the low percentage recovery of the transfected DNA. This may be verified by 
analysis of the supernatant from the wash steps. In the future, aliquots of the substrate 
DNA may be prepared following quantification, to prevent the denaturation of the biotin 
moiety due to repeated freeze-thaw. It may also be useful to optimize the volume and 
concentration of sodium hydroxide, and the incubation time for the denaturation step, to 
ensure that the coelution of the biotinylated DNA strand was not due to the conditions 
used for these steps. 
A commercially available competitive ELISA kit (Trevigen) was evaluated in this 
study for its specificity and efficiency in the detection of 8oxodG lesions on the +8oxodG 
DNA. The +8oxodG and -8oxodG DNA were used for this evaluation. The absorbance 
at 450 nm for the -8oxodG DNA was consistently at or near the readings obtained for the 
blank (0 ng/ml standard), while the readings for the +8oxodG DNA were lesser than the 
blank (lesser absorbance corresponds to more 8oxodG in competitive ELISA). This 
showed that the antibody specifically interacts with 8oxodG lesions. To determine 
conditions that improved specificity, the ELISA was performed using different blocking 
agents, primary antibody dilutions, and primary antibody incubation temperatures. It was 
observed that blocking the wells with 2% FBS gave high specificity when compared to 
10% FBS and 1% BSA. The specificity was also highest when incubating the +8oxodG 
or -8oxodG DNA in the wells at room temperature, with a 1/250 dilution of the primary 
antibody. The ELISA detected 8oxodG lesions on the +8oxodG DNA with an efficiency 
of 46.3% and also demonstrated the ability to detect the lesions on the +8oxodG DNA in 
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a dose-dependent manner, in the presence of the -8oxodG DNA. Thus, when used in the 
BER assay, the 8oxodG ELISA would effectively quantify lesions on the unrepaired 
target DNA in the presence of repaired target DNA. Thus, the competitive 8oxodG 
ELISA (Trevigen) with some modifications, was found to be suitable for use in our assay 
to specifically detect and quantify 8oxodG lesions on the +8oxodG DNA of the 
oligonucleotide DNA substrate. 
In summary, the design of a novel assay to measure the in vivo BER of 8oxodG 
lesions on an oligonucleotide DNA substrate was outlined in this study. The preparation 
of the substrate DNA and the optimal working conditions for the competitive ELISA 
were established. Preliminary experiments confirmed that the biotin-tagged substrate 
DNA can be successfully transfected into target cell cultures, and can be captured and 
purified using streptavidin-coated magnetic beads. By incubating cell cultures with the 
transfected substrate DNA for an increasing period of time, the steady-state 
measurements of BER activity in the cell may be obtained. In the future, the assay will 
have to be validated in vivo by comparing repair of the oligonucleotide DNA substrate in 
cell cultures that are known to possess functional BER versus those that do not. Since 
hOGGl is a critical enzyme involved in the repair of 8oxodG lesions, an isogenic system 
consisting of hOGGl knockout and hOGGl wild-type cells may be used for validating 
the assay. To this end, stable isogenic cell lines for hOGGl knockdown derived from 
MCF7 parental cell lines, have been developed at the Ford laboratory, and will be used to 
validate this assay in the future. Once validated, the assay may be used to confirm the 
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role of the BRCA1 protein, and investigate the role of other potential cancer-related 
proteins in the BER pathway. 
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CONCLUSION 
The 8oxodG lesions are some of the most frequently observed products of 
oxidative DNA damage in cells. Unless repaired by the BER pathway, these lesions 
could result in AP sites, strand breaks, genetic instability, and carcinogenesis. Defects in 
BER may occur due to germ-line or somatic mutations in the genes coding for 
BER-associated proteins. Defective cellular BER may be detected using assays, most of 
which are performed in vitro using cell protein extracts and radiolabeled reagents. A 
novel in vivo HCR assay for BER was recently developed in our laboratory. In chapter 
one of this thesis, we described the use of the HCR assay in SUM149PT cells to 
investigate the role of the BRCA1 protein in BER. An approximately two-fold increase 
in BER levels in cells transfected with the jBi?G47-wild type construct when compared to 
those transfected with the empty vector control was observed. This suggested that the 
BRCA1 protein was involved in the BER pathway. 
In order to corroborate the findings from chapter one, another in vivo assay for 
BER was necessary. In chapter two of this thesis, we described our design and 
optimization of a novel in vivo assay for BER. This assay monitors BER in target cells 
using a biotin-tagged, double-stranded, 8oxodG containing oligonucleotide DNA 
substrate, and an 8oxodG ELISA. Our assay offers an advantage over existing assays in 
that it measures the kinetics of BER in vivo and it does not use radiolabeled reagents. In 
the future, following validation of this assay in vivo, it may be used to confirm the role of 
the BRCA1 protein in BER. 
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